BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-1253. [PMID: 21726509 DOI: 10.1053/j.gastro.2011.06.061] [Cited by in Crossref: 770] [Cited by in F6Publishing: 657] [Article Influence: 77.0] [Reference Citation Analysis]
Number Citing Articles
1 Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. JGH Open 2018;2:235-41. [PMID: 30483595 DOI: 10.1002/jgh3.12070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
2 Aref MH, Aboughaleb IH, Youssef AM, El-Sharkawy YH. Hyperspectral image-based analysis of thermal damage for ex-vivo bovine liver utilizing radiofrequency ablation. Surg Oncol 2021;38:101564. [PMID: 33865183 DOI: 10.1016/j.suronc.2021.101564] [Reference Citation Analysis]
3 Peng K, Mo Z, Tian G. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males. Am J Med Sci 2017;353:236-41. [PMID: 28262209 DOI: 10.1016/j.amjms.2017.01.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
4 Tsai JH, Ferrell LD, Tan V, Yeh MM, Sarkar M, Gill RM. Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. Mod Pathol 2017;30:834-42. [PMID: 28256569 DOI: 10.1038/modpathol.2017.13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
5 Tien PC. Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy. Curr Atheroscler Rep 2015;17:73. [PMID: 26493063 DOI: 10.1007/s11883-015-0545-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
7 Valdecantos MP, Pardo V, Ruiz L, Castro-Sánchez L, Lanzón B, Fernández-Millán E, García-Monzón C, Arroba AI, González-Rodríguez Á, Escrivá F, Álvarez C, Rupérez FJ, Barbas C, Konkar A, Naylor J, Hornigold D, Santos AD, Bednarek M, Grimsby J, Rondinone CM, Valverde ÁM. A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatology 2017;65:950-68. [PMID: 27880981 DOI: 10.1002/hep.28962] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
8 Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995. [PMID: 24189085 DOI: 10.1136/bmjopen-2013-003995] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
9 Ashraf NU, Altaf M. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease. Mutat Res Rev Mutat Res 2018;778:1-12. [PMID: 30454678 DOI: 10.1016/j.mrrev.2018.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hanson A, Wilhelmsen D, DiStefano JK. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA 2018;4:E18. [PMID: 30134610 DOI: 10.3390/ncrna4030018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
11 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
12 Samji NS, Heda R, Satapathy SK. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . Transl Gastroenterol Hepatol 2020;5:10. [PMID: 32190778 DOI: 10.21037/tgh.2019.09.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Sase S, Takahashi H, Shigefuku R, Ikeda H, Kobayashi M, Matsumoto N, Suzuki M. Measurement of blood flow and xenon solubility coefficient in the human liver by xenon-enhanced computed tomography. Med Phys. 2012;39:7553-7559. [PMID: 23231303 DOI: 10.1118/1.4767759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Villeret F, Dumortier J, Erard-Poinsot D. How will NAFLD change the liver transplant landscape in the 2020s? Clin Res Hepatol Gastroenterol 2021;:101759. [PMID: 34311133 DOI: 10.1016/j.clinre.2021.101759] [Reference Citation Analysis]
15 Vildhede A, Kimoto E, Pelis RM, Rodrigues AD, Varma MV. Quantitative Proteomics and Mechanistic Modeling of Transporter‐Mediated Disposition in Nonalcoholic Fatty Liver Disease. Clin Pharmacol Ther 2020;107:1128-37. [DOI: 10.1002/cpt.1699] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
16 Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle. 2012;3:225-237. [PMID: 22648736 DOI: 10.1007/s13539-012-0069-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 130] [Article Influence: 16.8] [Reference Citation Analysis]
17 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703. [PMID: 30136293 DOI: 10.1111/apt.14937] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 23.7] [Reference Citation Analysis]
18 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Sasdelli AS, Brodosi L, Marchesini G. NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Curr Hepatology Rep 2016;15:103-12. [DOI: 10.1007/s11901-016-0297-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Mizokami-Stout K, Cree-Green M, Nadeau KJ. Insulin resistance in type 2 diabetic youth. Curr Opin Endocrinol Diabetes Obes 2012;19:255-62. [PMID: 22732484 DOI: 10.1097/MED.0b013e3283557cd5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
21 Valdecantos MP, Ruiz L, Pardo V, Castro-Sanchez L, García-Monzón C, Lanzón B, Rupérez J, Barbas C, Naylor J, Trevaskis JL, Grimsby J, Rondinone CM, Valverde ÁM. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. Sci Rep 2018;8:16461. [PMID: 30405191 DOI: 10.1038/s41598-018-33949-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
22 Reino DC, Weigle KE, Dutson EP, Bodzin AS, Lunsford KE, Busuttil RW. Liver transplantation and sleeve gastrectomy in the medically complicated obese: New challenges on the horizon. World J Hepatol 2015;7:2315-8. [PMID: 26413219 DOI: 10.4254/wjh.v7.i21.2315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chang AL, Cortez AR, Bondoc A, Schauer DP, Fitch A, Shah SA, Woodle SE, Diwan T. Metabolic syndrome in liver transplantation: A preoperative and postoperative concern. Surgery 2016;160:1111-7. [PMID: 27498302 DOI: 10.1016/j.surg.2016.06.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
24 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:3777-3785. [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 60] [Article Influence: 13.2] [Reference Citation Analysis]
25 Smith JD, Montaño Z, Maynard A, Miloh T. Family Functioning Predicts Body Mass Index and Biochemical Levels of Youths with Nonalcoholic Fatty Liver Disease. J Dev Behav Pediatr 2017;38:155-60. [PMID: 27984419 DOI: 10.1097/DBP.0000000000000379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11:1201-1204. [PMID: 23353640 DOI: 10.1016/j.cgh.2012.12.031] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 13.6] [Reference Citation Analysis]
27 Radwan MM, Radwan BM, Nandipati KC, Hunter WJ, Agrawal DK. Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Expert Rev Clin Immunol. 2013;9:727-738. [PMID: 23971751 DOI: 10.1586/1744666x.2013.816484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
28 Pisano G, Fracanzani AL, Caccamo L, Donato MF, Fargion S. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol. 2016;22:8869-8882. [PMID: 27833378 DOI: 10.3748/wjg.v22.i40.8869] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
29 Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, Toor A. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024-1030. [PMID: 25354830 DOI: 10.1007/s10620-014-3380-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 11.4] [Reference Citation Analysis]
30 Andrade ARCF, Cotrim HP, Bittencourt PL, Almeida CG, Sorte NCAB. Nonalcoholic steatohepatitis in posttransplantation liver: Review article. Rev Assoc Med Bras (1992). 2018;64:187-194. [PMID: 29641680 DOI: 10.1590/1806-9282.64.02.187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
31 Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33:86-98. [PMID: 28692197 DOI: 10.1111/jgh.13856] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 27.5] [Reference Citation Analysis]
32 Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019;25:2229-39. [PMID: 31143073 DOI: 10.3748/wjg.v25.i18.2229] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1560] [Article Influence: 494.5] [Reference Citation Analysis]
34 Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2019;13:179-87. [PMID: 30791782 DOI: 10.1080/17474124.2019.1549989] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
35 Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208-1223. [PMID: 26997540 DOI: 10.1016/j.metabol.2016.02.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
36 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361-371. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 161] [Cited by in F6Publishing: 129] [Article Influence: 53.7] [Reference Citation Analysis]
37 Shirazi F, Wang J, Wong RJ. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. J Clin Exp Hepatol 2020;10:30-6. [PMID: 32025164 DOI: 10.1016/j.jceh.2019.06.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
38 Patel P, Muller C, Paul S. Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis. World J Hepatol 2020;12:506-18. [PMID: 32952877 DOI: 10.4254/wjh.v12.i8.506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Li T, Yang Y, Song H, Li H, Cui A, Liu Y, Su L, Crispe IN, Tu Z. Activated NK cells kill hepatic stellate cells via p38/PI3K signaling in a TRAIL-involved degranulation manner. J Leukoc Biol. 2019;105:695-704. [PMID: 30748035 DOI: 10.1002/jlb.2a0118-031rr] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
40 Thuluvath AJ, Chen PH, Thuluvath PJ, Kantsevoy S, Savva Y. Poor Survival After Retransplantation in NASH Cirrhosis. Transplantation 2019;103:101-8. [PMID: 29470354 DOI: 10.1097/TP.0000000000002135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Reference Citation Analysis]
42 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
43 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
44 Del Ben M, Baratta F, Polimeni L, Angelico F. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg Med. 2012;7 Suppl 3:S291-S296. [PMID: 23073870 DOI: 10.1007/s11739-012-0819-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
45 Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol. 2014;6:306-314. [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
46 Sanyal AJ, Miller V. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis. Gastroenterology 2016;150:1723-7. [PMID: 26924092 DOI: 10.1053/j.gastro.2016.02.044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
47 Ayloo S, Pentakota SR, Molinari M. Trends of characteristics and outcomes of donors and recipients of deceased donor liver transplantation in the United States: 1990 to 2013. World J Transplant 2018;8:167-77. [PMID: 30211025 DOI: 10.5500/wjt.v8.i5.167] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Valenzuela R, Videla LA. Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View. Nutrients. 2020;12. [PMID: 32075238 DOI: 10.3390/nu12020499] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 32.0] [Reference Citation Analysis]
49 Xanthakos SA, Kohli R. Treating Pediatric Nonalcoholic Fatty Liver Disease with Cysteamine: Is Adiponectin the Key? The Journal of Pediatrics 2012;161:579-81. [DOI: 10.1016/j.jpeds.2012.05.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263-8276. [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 234] [Cited by in F6Publishing: 187] [Article Influence: 78.0] [Reference Citation Analysis]
51 Ling J, Chaba T, Zhu LF, Jacobs RL, Vance DE. Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice. Hepatology 2012;55:1094-102. [PMID: 22095799 DOI: 10.1002/hep.24782] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
52 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
53 Morling JR, Fallowfield JA, Williamson RM, Nee LD, Jackson AP, Glancy S, Reynolds RM, Hayes PC, Guha IN, Strachan MWJ, Price JF. Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Liver Int 2014;34:1267-77. [DOI: 10.1111/liv.12385] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637-653. [PMID: 25194181 DOI: 10.1016/j.bpg.2014.07.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 146] [Article Influence: 27.0] [Reference Citation Analysis]
55 Liss KHH, Ek SE, Lutkewitte AJ, Pietka TA, He M, Skaria P, Tycksen E, Ferguson D, Blanc V, Graham MJ, Hall AM, McGill MR, McCommis KS, Finck BN. Monoacylglycerol Acyltransferase 1 Knockdown Exacerbates Hepatic Ischemia/Reperfusion Injury in Mice With Hepatic Steatosis. Liver Transpl 2021;27:116-33. [PMID: 32916011 DOI: 10.1002/lt.25886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Kern B, Feurstein B, Fritz J, Fabritius C, Sucher R, Graziadei I, Bale R, Tilg H, Zoller H, Newsome P, Eschertzhuber S, Margreiter R, Öfner D, Schneeberger S. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. Eur J Gastroenterol Hepatol 2019;31:205-10. [PMID: 30320609 DOI: 10.1097/MEG.0000000000001270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
57 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
58 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67:549-559. [PMID: 28892558 DOI: 10.1002/hep.29514] [Cited by in Crossref: 249] [Cited by in F6Publishing: 234] [Article Influence: 62.3] [Reference Citation Analysis]
59 Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. Am J Gastroenterol 2016;111:658-64. [PMID: 27002796 DOI: 10.1038/ajg.2016.57] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
60 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165. [PMID: 24716201 DOI: 10.1002/hep.26972] [Cited by in Crossref: 429] [Cited by in F6Publishing: 276] [Article Influence: 61.3] [Reference Citation Analysis]
62 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 18.5] [Reference Citation Analysis]
63 Wang Y, Vincent R, Yang J, Asgharpour A, Liang X, Idowu MO, Contos MJ, Daitya K, Siddiqui MS, Mirshahi F, Sanyal AJ. Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis. Hepatology 2017;65:1891-903. [PMID: 28133774 DOI: 10.1002/hep.29090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
64 Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, Mathurin P, Gournay J, Nguyen-khac E, De Ledinghen V, Larrey D, Tran A, Bourliere M, Maynard-muet M, Asselah T, Henrion J, Nevens F, Cassiman D, Geerts A, Moreno C, Beuers U, Galle P, Spengler U, Bugianesi E, Craxi A, Angelico M, Fargion S, Voiculescu M, Gheorghe L, Preotescu L, Caballeria J, Andrade R, Crespo J, Callera J, Ala A, Aithal G, Abouda G, Luketic V, Huang M, Gordon S, Pockros P, Poordad F, Shores N, Moehlen M, Bambha K, Clark V, Satapathy S, Parekh S, Reddy R, Sheikh M, Szabo G, Vierling J, Foster T, Umpierrez G, Chang C, Box T, Gallegos-orozco J. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016;150:1147-1159.e5. [DOI: 10.1053/j.gastro.2016.01.038] [Cited by in Crossref: 533] [Cited by in F6Publishing: 461] [Article Influence: 106.6] [Reference Citation Analysis]
65 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, Peyvandi F, Bertelli C, Valenti L, Fargion S. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61:148-154. [PMID: 24657400 DOI: 10.1016/j.jhep.2014.03.013] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 12.1] [Reference Citation Analysis]
67 Cai C, Song X, Chen Y, Chen X, Yu C. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatol Int 2020;14:115-26. [PMID: 31290072 DOI: 10.1007/s12072-019-09964-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
68 Britton LJ, Subramaniam VN, Crawford DH. Iron and non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22:8112-8122. [PMID: 27688653 DOI: 10.3748/wjg.v22.i36.8112] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 38] [Article Influence: 12.5] [Reference Citation Analysis]
69 Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology 2014;147:377-384.e1. [DOI: 10.1053/j.gastro.2014.04.046] [Cited by in Crossref: 195] [Cited by in F6Publishing: 164] [Article Influence: 27.9] [Reference Citation Analysis]
70 Liss KH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie 2017;136:65-74. [PMID: 27916647 DOI: 10.1016/j.biochi.2016.11.009] [Cited by in Crossref: 103] [Cited by in F6Publishing: 85] [Article Influence: 20.6] [Reference Citation Analysis]
71 Bilbao I, Dopazo C, Lazaro J, Castells L, Caralt M, Sapisochin G, Charco R. Multiple indications for everolimus after liver transplantation in current clinical practice. World J Transplant 2014;4:122-32. [PMID: 25032101 DOI: 10.5500/wjt.v4.i2.122] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
72 Alkhouri N, Kohli R, Feldstein AE. Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints. Hepatol Commun 2019;3:1563-70. [PMID: 31832567 DOI: 10.1002/hep4.1449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Mehta R, Birerdinc A, Younossi ZM. Host genetic variants in obesity-related nonalcoholic fatty liver disease. Clin Liver Dis 2014;18:249-67. [PMID: 24274878 DOI: 10.1016/j.cld.2013.09.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
74 Machado MV, Michelotti GA, Pereira Tde A, Boursier J, Kruger L, Swiderska-Syn M, Karaca G, Xie G, Guy CD, Bohinc B. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut. 2015;64:1148-1157. [PMID: 25053716 DOI: 10.1136/gutjnl-2014-307362] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
75 Terjimanian MN, Harbaugh CM, Hussain A, Olugbade KO Jr, Waits SA, Wang SC, Sonnenday CJ, Englesbe MJ. Abdominal adiposity, body composition and survival after liver transplantation. Clin Transplant. 2016;30:289-294. [PMID: 26717257 DOI: 10.1111/ctr.12688] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
76 Ezzaidi N, Zhang X, Coker OO, Yu J. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. Cancer Lett 2019;459:186-91. [PMID: 31185249 DOI: 10.1016/j.canlet.2019.114425] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
77 Choi YJ, Lee DH, Han KD, Yoon H, Shin CM, Park YS, Kim N. Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. PLoS One 2018;13:e0201308. [PMID: 30231041 DOI: 10.1371/journal.pone.0201308] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
78 Sun X, Zhu S, Dong X, Strand-Amundsen RJ, Tonnessen TI, Yang R. Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis. Biomed Pharmacother 2021;137:111392. [PMID: 33761609 DOI: 10.1016/j.biopha.2021.111392] [Reference Citation Analysis]
79 Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, Giamberardino MA, Cipollone F, Sutton R, Vettor R, Fedorowski A, Meschi T. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16. [PMID: 31455011 DOI: 10.3390/ijerph16173104] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 23.5] [Reference Citation Analysis]
80 Singal AK, Charlton M. Transplantation for Nonalcoholic Steatohepatitis. Transplantation of the Liver. Elsevier; 2015. pp. 250-5. [DOI: 10.1016/b978-1-4557-0268-8.00022-1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
81 El Kassas M, Alboraie M, Al Balakosy A, Abdeen N, Afify S, Abdalgaber M, Sherief AF, Madkour A, Abdellah Ahmed M, Eltabbakh M, Salaheldin M, Wifi MN. Liver transplantation in the era of COVID-19. Arab J Gastroenterol. 2020;21:69-75. [PMID: 32439237 DOI: 10.1016/j.ajg.2020.04.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
82 Stine JG, Schreibman I, Navabi S, Kang M, Dahmus J, Soriano C, Rivas G, Hummer B, Beyer M, Tressler H, Kimball SR, Patterson AD, Schmitz K, Sciamanna C. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH. Contemp Clin Trials Commun 2020;18:100560. [PMID: 32309672 DOI: 10.1016/j.conctc.2020.100560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
83 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 158] [Article Influence: 37.2] [Reference Citation Analysis]
86 Ratziu V. Back to Byzance: Querelles byzantines over NASH and fibrosis. Journal of Hepatology 2017;67:1134-6. [DOI: 10.1016/j.jhep.2017.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
87 Koshy AN, Gow PJ, Han HC, Teh AW, Jones R, Testro A, Lim HS, McCaughan G, Jeffrey GP, Crawford M, Macdonald G, Fawcett J, Wigg A, Chen JWC, Gane EJ, Munn SR, Clark DJ, Yudi MB, Farouque O. Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. Eur Heart J Qual Care Clin Outcomes 2020;6:243-53. [PMID: 32011663 DOI: 10.1093/ehjqcco/qcaa009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
88 Patel SS, Nabi E, Guzman L, Abbate A, Bhati C, Stravitz RT, Reichman T, Matherly SC, Driscoll C, Lee H, Luketic VA, Sterling RK, Sanyal AJ, Patel V, Levy M, Siddiqui MS. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transpl. 2018;24:333-342. [PMID: 29328556 DOI: 10.1002/lt.25012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 13.3] [Reference Citation Analysis]
89 Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726-735. [PMID: 24316260 DOI: 10.1053/j.gastro.2013.11.049] [Cited by in Crossref: 443] [Cited by in F6Publishing: 388] [Article Influence: 55.4] [Reference Citation Analysis]
90 Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology. 2016;150:1835-1848. [PMID: 26971824 DOI: 10.1053/j.gastro.2016.03.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 10.2] [Reference Citation Analysis]
91 Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15532-15538. [PMID: 25400437 DOI: 10.3748/wjg.v20.i42.15532] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 76] [Article Influence: 16.3] [Reference Citation Analysis]
92 Hagström H, Nasr P, Ekstedt M, Kechagias S, Stål P, Bedossa P, Hultcrantz R. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scandinavian Journal of Gastroenterology 2017;52:87-91. [DOI: 10.1080/00365521.2016.1230779] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
93 Morrison MC, Mulder P, Salic K, Verheij J, Liang W, van Duyvenvoorde W, Menke A, Kooistra T, Kleemann R, Wielinga PY. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice. Int J Obes (Lond) 2016;40:1416-23. [PMID: 27121255 DOI: 10.1038/ijo.2016.74] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
94 Danford CJ, Iriana S, Shen C, Curry MP, Lai M. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients. Liver Int 2019;39:1165-73. [PMID: 30809932 DOI: 10.1111/liv.14080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
95 Festi D, Schiumerini R, Marasco G, Scaioli E, Pasqui F, Colecchia A. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology 2015;9:1039-53. [DOI: 10.1586/17474124.2015.1049155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
96 Asrani SK, O’leary JG. The Changing Liver Transplant Waitlist: An Emerging Liver Purgatory? Gastroenterology 2015;148:493-6. [DOI: 10.1053/j.gastro.2015.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
97 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Loher H, Kreis R, Boesch C, Christ E. The Flexibility of Ectopic Lipids. Int J Mol Sci 2016;17:E1554. [PMID: 27649157 DOI: 10.3390/ijms17091554] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
99 Holterman AX, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, Holterman M. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity (Silver Spring). 2013;21:591-597. [PMID: 23592668 DOI: 10.1002/oby.20174] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
100 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 2014;5:277-286. [PMID: 25285192 DOI: 10.1136/flgastro-2013-100404] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 8.6] [Reference Citation Analysis]
101 Dyson JK, Anstee QM, McPherson S. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J 2015;91:92-101. [PMID: 25655252 DOI: 10.1136/postgradmedj-2013-100404rep] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
102 Elsharkawy AM, Hudson M. The future developments in hepatology: no need for a jaundiced view. Frontline Gastroenterol 2012;3:i47-52. [PMID: 28839693 DOI: 10.1136/flgastro-2012-100153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Engin A. Non-Alcoholic Fatty Liver Disease. In: Engin AB, Engin A, editors. Obesity and Lipotoxicity. Cham: Springer International Publishing; 2017. pp. 443-67. [DOI: 10.1007/978-3-319-48382-5_19] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 21.3] [Reference Citation Analysis]
104 Heebøll S, Thomsen KL, Pedersen SB, Vilstrup H, George J, Grønbæk H. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol 2014;6:188-98. [PMID: 24799987 DOI: 10.4254/wjh.v6.i4.188] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
105 Udompap P, Kim D, Kim WR. Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol. 2015;13:2031-2041. [PMID: 26291665 DOI: 10.1016/j.cgh.2015.08.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 11.5] [Reference Citation Analysis]
106 Mahady SE, George J. The future liver of the Asia pacific: fatter and firmer from more fructose and fortune? J Clin Exp Hepatol 2013;3:106-13. [PMID: 25755484 DOI: 10.1016/j.jceh.2012.10.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
107 DiCecco SR, Francisco-Ziller N. Obesity and organ transplantation: successes, failures, and opportunities. Nutr Clin Pract. 2014;29:171-191. [PMID: 24503157 DOI: 10.1177/0884533613518585] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
108 Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism 2016;65:1007-16. [DOI: 10.1016/j.metabol.2015.12.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
109 Lynch C, Chan CS, Drake AJ. Early life programming and the risk of non-alcoholic fatty liver disease. J Dev Orig Health Dis 2017;8:263-72. [DOI: 10.1017/s2040174416000805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
110 Tu LN, Showalter MR, Cajka T, Fan S, Pillai VV, Fiehn O, Selvaraj V. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep 2017;7:6120. [PMID: 28733574 DOI: 10.1038/s41598-017-05040-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
111 Misciagna G, del Pilar Díaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, Chiloiro M, Abbrescia DI, Mirizzi A, Tanzi M, Caruso MG, Correale M, Reddavide R, Inguaggiato R, Cisternino AM, Osella AR. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging 2017;21:404-12. [DOI: 10.1007/s12603-016-0809-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
112 Jobira B, Frank DN, Silveira LJ, Pyle L, Kelsey MM, Garcia-Reyes Y, Robertson CE, Ir D, Nadeau KJ, Cree-Green M. Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome. PLoS One 2021;16:e0245219. [PMID: 33465100 DOI: 10.1371/journal.pone.0245219] [Reference Citation Analysis]
113 Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 433] [Article Influence: 63.3] [Reference Citation Analysis]
114 Dichtel LE, Corey KE, Misdraji J, Bredella MA, Schorr M, Osganian SA, Young BJ, Sung JC, Miller KK. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2017;8:e217. [PMID: 28125073 DOI: 10.1038/ctg.2016.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
115 Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol 2018;30:1103-15. [PMID: 30113367 DOI: 10.1097/MEG.0000000000001235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
116 Saab S, Lalezari D, Pruthi P, Alper T, Tong MJ. The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. Liver Int. 2015;35:164-170. [PMID: 24313970 DOI: 10.1111/liv.12431] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 7.7] [Reference Citation Analysis]
117 Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362-373. [PMID: 32027858 DOI: 10.1016/s2468-1253(19)30383-8] [Cited by in Crossref: 96] [Cited by in F6Publishing: 32] [Article Influence: 96.0] [Reference Citation Analysis]
118 Rodrigues RM, Branson S, De Boe V, Sachinidis A, Rogiers V, De Kock J, Vanhaecke T. In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Arch Toxicol 2016;90:677-89. [PMID: 25716160 DOI: 10.1007/s00204-015-1483-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
119 Dugum M, McCullough A. Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol 2015;3:109-16. [PMID: 26356792 DOI: 10.14218/JCTH.2015.00008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
120 Chhatrala R, Siddiqui MB, Stravitz RT, Driscoll C, Sanyal A, Sargeant C, Luketic V, Sharma A, Sterling R, Matherly S. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers. Liver Transpl. 2015;21:623-630. [PMID: 25762084 DOI: 10.1002/lt.24100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
121 Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl. 2015;21:1016-1021. [PMID: 25845711 DOI: 10.1002/lt.24134] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 12.2] [Reference Citation Analysis]
122 Valenzuela R, Ortiz M, Hernández-Rodas MC, Echeverría F, Videla LA. Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease. Curr Med Chem 2020;27:5250-72. [PMID: 30968772 DOI: 10.2174/0929867326666190410121716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
123 Zhu R, Baker SS, Moylan CA, Abdelmalek MF, Guy CD, Zamboni F, Wu D, Lin W, Liu W, Baker RD, Govindarajan S, Cao Z, Farci P, Diehl AM, Zhu L. Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers: Elevated alcohol-metabolizing genes in NAFLD. J Pathol 2016;238:531-42. [DOI: 10.1002/path.4650] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
124 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 104] [Article Influence: 25.8] [Reference Citation Analysis]
125 van Baar ACG, Beuers U, Wong K, Haidry R, Costamagna G, Hafedi A, Deviere J, Ghosh SS, Lopez-Talavera JC, Rodriguez L, Galvao Neto MP, Sanyal A, Bergman JJGHM. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Rep 2019;1:429-37. [PMID: 32039394 DOI: 10.1016/j.jhepr.2019.10.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
126 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2017;. [PMID: 28892558 DOI: 10.1002/hep.29514.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Wang CW, Covinsky KE, Feng S, Hayssen H, Segev DL, Lai JC. Functional impairment in older liver transplantation candidates: From the functional assessment in liver transplantation study. Liver Transpl 2015;21:1465-70. [PMID: 26359787 DOI: 10.1002/lt.24334] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
128 Gadiparthi C, Spatz M, Greenberg S, Iqbal U, Kanna S, Satapathy SK, Broder A, Ahmed A. NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. J Clin Transl Hepatol. 2020;8:215-221. [PMID: 32832402 DOI: 10.14218/jcth.2020.00014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
129 Atamni HJA, Botzman M, Mott R, Gat-viks I, Iraqi FA. Mapping liver fat female-dependent quantitative trait loci in collaborative cross mice. Mamm Genome 2016;27:565-73. [DOI: 10.1007/s00335-016-9658-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
130 Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, Feurstein B, Popp W, Karam V, Muiesan P, O'Grady J, Jamieson N, Wigmore SJ, Pirenne J, Malek-Hosseini SA, Hidalgo E, Tokat Y, Paul A, Pratschke J, Bartels M, Trunecka P, Settmacher U, Pinzani M, Duvoux C, Newsome PN, Schneeberger S; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019;71:313-322. [PMID: 31071367 DOI: 10.1016/j.jhep.2019.04.011] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 35.5] [Reference Citation Analysis]
131 Ochoa‐allemant P, Ezaz G, Trivedi HD, Sanchez‐fernandez L, Bonder A. Long‐term outcomes after liver transplantation in the Hispanic population. Liver Int 2020;40:437-46. [DOI: 10.1111/liv.14248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
132 Said A. Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. World J Gastroenterol. 2013;19:9146-9155. [PMID: 24409043 DOI: 10.3748/wjg.v19.i48.9146] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
133 Seko Y, Yamaguchi K, Itoh Y. The genetic backgrounds in nonalcoholic fatty liver disease. Clin J Gastroenterol 2018;11:97-102. [DOI: 10.1007/s12328-018-0841-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
134 Tsamalaidze L, Stauffer JA, Arasi LC, Villacreses DE, Franco JSS, Bowers S, Elli EF. Laparoscopic Sleeve Gastrectomy for Morbid Obesity in Patients After Orthotopic Liver Transplant: a Matched Case-Control Study. Obes Surg. 2018;28:444-450. [PMID: 28766265 DOI: 10.1007/s11695-017-2847-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
135 Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug Metab Dispos 2015;43:1484-90. [DOI: 10.1124/dmd.115.065979] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
136 Nagai S, Collins K, Chau LC, Safwan M, Rizzari M, Yoshida A, Abouljoud MS, Moonka D. Increased Risk of Death in First Year After Liver Transplantation Among Patients With Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies. Clinical Gastroenterology and Hepatology 2019;17:2759-2768.e5. [DOI: 10.1016/j.cgh.2019.04.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
137 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 150] [Article Influence: 38.0] [Reference Citation Analysis]
138 Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci Transl Med 2017;9:eaal3694. [PMID: 28659437 DOI: 10.1126/scitranslmed.aal3694] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 20.3] [Reference Citation Analysis]
139 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
140 Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019;70:1913-1927. [PMID: 30993748 DOI: 10.1002/hep.30664] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 37.5] [Reference Citation Analysis]
141 Toniutto P, Bitetto D, Fornasiere E, Fumolo E. Challenges and future developments in liver transplantation. Minerva Gastroenterol Dietol 2019;65:136-52. [PMID: 30303340 DOI: 10.23736/S1121-421X.18.02529-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
142 Elbel EE, Lavine JE, Downes M, Van Natta M, Yu R, Schwimmer JB, Behling C, Brunt EM, Tonascia J, Evans R. Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease. Hepatol Commun 2018;2:1213-26. [PMID: 30288476 DOI: 10.1002/hep4.1232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
143 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
144 Steggerda JA, Mahendraraj K, Todo T, Noureddin M. Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. World J Gastroenterol 2020;26:4018-35. [PMID: 32821068 DOI: 10.3748/wjg.v26.i28.4018] [Reference Citation Analysis]
145 Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22-29. [PMID: 22554256 DOI: 10.1111/j.1365-2036.2012.05121.x] [Cited by in Crossref: 226] [Cited by in F6Publishing: 188] [Article Influence: 25.1] [Reference Citation Analysis]
146 Kolachala VL, Palle S, Shen M, Feng A, Shayakhmetov D, Gupta NA. Loss of L-selectin-guided CD8+ , but not CD4+ , cells protects against ischemia reperfusion injury in a steatotic liver. Hepatology 2017;66:1258-74. [PMID: 28543181 DOI: 10.1002/hep.29276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
147 Bishay RH, Meyerowitz-Katz G, Hng TM, Colaco CMG, Khanna S, Klein R, Sanjeev D, McLean M, Ahlenstiel G, Maberly GF. A retrospective case-control cohort analysis of comorbidity and health expenditure in hospitalized adults diagnosed with obesity utilizing ICD-10 diagnostic coding. Clin Obes 2021;:e12469. [PMID: 34053198 DOI: 10.1111/cob.12469] [Reference Citation Analysis]
148 Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. Clin Transplant. 2014;28:713-721. [PMID: 24654688 DOI: 10.1111/ctr.12364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
149 Yu JW, Gupta G, Kang L, Bandyopadhyay D, Siddiqui MS, Bhati CS, Stravitz RT, Levy M, Reichman TW. Obesity does not significantly impact outcomes following simultaneous liver kidney transplantation: review of the UNOS database - a retrospective study. Transpl Int 2019;32:206-17. [DOI: 10.1111/tri.13352] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
150 Nobili V, de Ville de Goyet J. Pediatric post-transplant metabolic syndrome: new clouds on the horizon. Pediatr Transplant 2013;17:216-23. [PMID: 23496113 DOI: 10.1111/petr.12065] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
151 Mahady SE, Gale J, Macaskill P, Craig JC, George J. Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross-sectional study of 9,447 people: Elevated alanine transaminase in Australia. Journal of Gastroenterology and Hepatology 2017;32:169-76. [DOI: 10.1111/jgh.13434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
152 Pani A, Giossi R, Menichelli D, Fittipaldo VA, Agnelli F, Inglese E, Romandini A, Roncato R, Pintaudi B, Del Sole F, Scaglione F. Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients 2020;12:E3379. [PMID: 33153126 DOI: 10.3390/nu12113379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
153 Baltieri L, Chaim EA, Chaim FDM, Utrini MP, Gestic MA, Cazzo E. CORRELATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE FEATURES AND LEVELS OF ADIPOKINES AND INFLAMMATORY CYTOKINES AMONG MORBIDLY OBESE INDIVIDUALS. Arq Gastroenterol 2018;55:247-51. [DOI: 10.1590/s0004-2803.201800000-62] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
154 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 133] [Article Influence: 19.9] [Reference Citation Analysis]
155 Hodson L, Brouwers MCGJ. Non-alcoholic fatty liver disease concerns with glucokinase activators. The Lancet Diabetes & Endocrinology 2018;6:684-5. [DOI: 10.1016/s2213-8587(18)30196-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
156 Strohäker J, Königsrainer A, Nadalin S. [Role of the radiologist in surgery of colorectal liver metastases : What should be removed and what must remain]. Radiologe 2019;59:791-8. [PMID: 31410495 DOI: 10.1007/s00117-019-0577-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:23-31. [PMID: 26111358 DOI: 10.1111/jgh.13026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 10.6] [Reference Citation Analysis]
158 Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Ho YL, Yang WS. Nonalcoholic Fatty Liver Disease Is Associated With QT Prolongation in the General Population. J Am Heart Assoc. 2015;4:pii e001820. [PMID: 26199227 DOI: 10.1161/jaha.115.001820] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
159 Durkin N, Desai AP. What Is the Evidence for Paediatric/Adolescent Bariatric Surgery? Curr Obes Rep 2017;6:278-85. [PMID: 28815416 DOI: 10.1007/s13679-017-0277-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
160 Pydyn N, Miękus K, Jura J, Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep 2020;72:1-12. [PMID: 32016853 DOI: 10.1007/s43440-019-00020-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
161 Charlton MR. ChREBP in NASH - a liver transcription factor comes in from the cold. J Hepatol 2013;59:178-9. [PMID: 23523581 DOI: 10.1016/j.jhep.2013.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
162 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
163 Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017;62:2915-2922. [PMID: 28744836 DOI: 10.1007/s10620-017-4684-x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 99] [Article Influence: 28.3] [Reference Citation Analysis]
164 Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology 2016;64:2165-72. [DOI: 10.1002/hep.28812] [Cited by in Crossref: 78] [Cited by in F6Publishing: 56] [Article Influence: 15.6] [Reference Citation Analysis]
165 Issa D, Wattacheril J, Sanyal AJ. Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opin Drug Saf. 2017;16:903-913. [PMID: 28641031 DOI: 10.1080/14740338.2017.1343299] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
166 O'Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B, Morgan G, Hebditch V, Jönsson B, Mabhala M, Reic T, Van Thiel I, Ratziu V, Romero-Gomez M, Bugianesi E, Schattenberg JM, Anstee QM. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep 2020;2:100142. [PMID: 32775976 DOI: 10.1016/j.jhepr.2020.100142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
167 Verbeek J, Jacobs A, Spincemaille P, Cassiman D. Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis. Curr Protoc Mouse Biol 2016;6:201-10. [PMID: 27248435 DOI: 10.1002/cpmo.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
168 Thoefner LB, Rostved AA, Pommergaard HC, Rasmussen A. Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2018;32:69-77. [PMID: 28501338 DOI: 10.1016/j.trre.2017.03.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
169 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-690. [PMID: 24042449 DOI: 10.1038/nrgastro.2013.171] [Cited by in Crossref: 926] [Cited by in F6Publishing: 833] [Article Influence: 115.8] [Reference Citation Analysis]
170 Petitclerc L, Gilbert G, Nguyen BN, Tang A. Liver Fibrosis Quantification by Magnetic Resonance Imaging. Top Magn Reson Imaging 2017;26:229-41. [PMID: 28858038 DOI: 10.1097/RMR.0000000000000149] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
171 He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016;95:e4947. [PMID: 27759627 DOI: 10.1097/MD.0000000000004947] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
172 Ibáñez-Samaniego L, Catalina MV, Rincón D, Lo Iacono O, Fernández A, Clemente G, Bañares R, Vaquero J, Salcedo M. Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After Liver Transplantation. Ther Apher Dial 2016;20:189-96. [PMID: 26929255 DOI: 10.1111/1744-9987.12381] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
173 Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology. 2017;65:1156-1164. [PMID: 27880977 DOI: 10.1002/hep.28958] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
174 Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract 2015;108:466-72. [PMID: 25836944 DOI: 10.1016/j.diabres.2015.02.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
175 Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:394-402.e1. [PMID: 24076414 DOI: 10.1016/j.cgh.2013.09.023] [Cited by in Crossref: 102] [Cited by in F6Publishing: 85] [Article Influence: 12.8] [Reference Citation Analysis]
176 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
177 Sanyal AJ, Neuschwander-Tetri BA, Tonascia J. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. Gastroenterology 2016;150:11-3. [PMID: 26602217 DOI: 10.1053/j.gastro.2015.11.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
178 ASGE Bariatric Endoscopy Task Force. ASGE Technology Committee, Abu Dayyeh BK, Edmundowicz SA, Jonnalagadda S, Kumar N, Larsen M, Sullivan S, Thompson CC, Banerjee S. Endoscopic bariatric therapies. Gastrointest Endosc. 2015;81:1073-1086. [PMID: 25828245 DOI: 10.1016/j.gie.2015.02.023] [Cited by in Crossref: 93] [Cited by in F6Publishing: 53] [Article Influence: 15.5] [Reference Citation Analysis]
179 Green CH, Syn WK. Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature. Eur J Nutr 2019;58:1785-800. [PMID: 31119399 DOI: 10.1007/s00394-019-01996-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
180 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 214] [Article Influence: 49.6] [Reference Citation Analysis]
181 Narayanan S, Surette FA, Hahn YS. The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Netw 2016;16:147-58. [PMID: 27340383 DOI: 10.4110/in.2016.16.3.147] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
182 Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2016;17:1937-46. [DOI: 10.1080/14656566.2016.1225727] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
183 Jahn D, Dorbath D, Kircher S, Nier A, Bergheim I, Lenaerts K, Hermanns HM, Geier A. Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis. Nutrients. 2019;11:77. [PMID: 30609782 DOI: 10.3390/nu11010077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
184 Dimou FM, Mehta HB, Adhikari D, Harland RC, Riall TS, Kuo YF. The role of extended criteria donors in liver transplantation for nonalcoholic steatohepatitis. Surgery 2016;160:1533-43. [PMID: 27554622 DOI: 10.1016/j.surg.2016.06.051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
185 Jung SY, Lee YJ, Lee HJ, Lee YA, Moon JS, Ko JS, Yang SW, Shin CH. Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma. Ann Pediatr Endocrinol Metab 2017;22:189-96. [PMID: 29025206 DOI: 10.6065/apem.2017.22.3.189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
186 Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015. World J Hepatol 2015;7:2962-7. [PMID: 26730275 DOI: 10.4254/wjh.v7.i30.2962] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
187 Spiritos Z, Abdelmalek MF. Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:13. [PMID: 33409407 DOI: 10.21037/tgh.2020.02.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Ayloo S, Hurton S, Cwinn M, Molinari M. Impact of body mass index on outcomes of 48281 patients undergoing first time cadaveric liver transplantation. World J Transplant 2016;6:356-69. [PMID: 27358781 DOI: 10.5500/wjt.v6.i2.356] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
189 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
190 Nguyen V, Li J, Gan J, Cordero P, Ray S, Solis-Cuevas A, Khatib M, Oben JA. Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre. Can J Gastroenterol Hepatol 2017;2017:4697194. [PMID: 29441342 DOI: 10.1155/2017/4697194] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
191 Simons N, Bijnen M, Wouters KAM, Rensen SS, Beulens JWJ, van Greevenbroek MMJ, 't Hart LM, Greve JWM, van der Kallen CJH, Schaper NC, Schalkwijk CG, Stehouwer CDA, Brouwers MCGJ. The endothelial function biomarker soluble E-selectin is associated with nonalcoholic fatty liver disease. Liver Int 2020;40:1079-88. [PMID: 31960587 DOI: 10.1111/liv.14384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
192 Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425-443. [PMID: 27091791 DOI: 10.1016/j.jhep.2016.04.005] [Cited by in Crossref: 190] [Cited by in F6Publishing: 167] [Article Influence: 38.0] [Reference Citation Analysis]
193 Su F, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, Reyes JD, Ioannou GN. Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. Gastroenterology. 2016;150:441-453.e6; quiz e16. [PMID: 26522262 DOI: 10.1053/j.gastro.2015.10.043] [Cited by in Crossref: 86] [Cited by in F6Publishing: 63] [Article Influence: 14.3] [Reference Citation Analysis]
194 Videla LA, Pettinelli P. Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res. 2012;2012:107434. [PMID: 23304111 DOI: 10.1155/2012/107434] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
195 Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95:314-322. [PMID: 31085617 DOI: 10.1136/postgradmedj-2018-136316] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
196 Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145:375-382.e1-2. [PMID: 23583430 DOI: 10.1053/j.gastro.2013.04.005] [Cited by in Crossref: 172] [Cited by in F6Publishing: 143] [Article Influence: 21.5] [Reference Citation Analysis]
197 Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134-143. [PMID: 23718573 DOI: 10.1111/apt.12352] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 14.1] [Reference Citation Analysis]
198 Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol. 2015;7:2811-2818. [PMID: 26668692 DOI: 10.4254/wjh.v7.i28.2811] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
199 Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092-2103.e1-6. [PMID: 24582567 DOI: 10.1016/j.cgh.2014.02.024] [Cited by in Crossref: 172] [Cited by in F6Publishing: 154] [Article Influence: 24.6] [Reference Citation Analysis]
200 Feng Q, Liu W, Baker SS, Li H, Chen C, Liu Q, Tang S, Guan L, Tsompana M, Kozielski R, Baker RD, Peng J, Liu P, Zhu R, Hu Y, Zhu L. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease. Oncotarget. 2017;8:27820-27838. [PMID: 28416740 DOI: 10.18632/oncotarget.15482] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
201 Russ TC, Kivimäki M, Morling JR, Starr JM, Stamatakis E, Batty GD. Association Between Psychological Distress and Liver Disease Mortality: A Meta-analysis of Individual Study Participants. Gastroenterology 2015;148:958-966.e4. [PMID: 25680670 DOI: 10.1053/j.gastro.2015.02.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
202 Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol 2015;3:78-84. [PMID: 26357637 DOI: 10.14218/JCTH.2014.00037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
203 Graziadei IW. Recurrence of nonviral liver diseases after liver transplantation. Clin Liver Dis. 2014;18:675-685. [PMID: 25017083 DOI: 10.1016/j.cld.2014.05.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
204 Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012;18:1029-1036. [PMID: 22641474 DOI: 10.1002/lt.23479] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
205 Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47:266-280. [PMID: 28019064 DOI: 10.1111/hepr.12856] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
206 Watt KD. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl. 2012;18 Suppl 2:S52-S58. [PMID: 22821716 DOI: 10.1002/lt.23515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
207 Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, Abrigo JM, Chan RS, Woo J, Tse YK, Chu WC, Chan HL. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62:182-189. [PMID: 25195550 DOI: 10.1016/j.jhep.2014.08.041] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 13.4] [Reference Citation Analysis]
208 Henson JB, Wilder JM, Kappus MR, Barbas AS, Moylan CA, Niedzwiecki D, Muir AJ, Berg CL, Patel YA. Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C. Transplantation 2020;104:e164-73. [PMID: 32150036 DOI: 10.1097/TP.0000000000003219] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
209 Gitto S, Marra F, De Maria N, Bihl F, Villa E, Andreone P, Burra P. Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. Expert Review of Gastroenterology & Hepatology 2018;13:173-8. [DOI: 10.1080/17474124.2019.1551132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
210 Heimbach J. Debate: A bridge too far--liver transplantation for nonalcoholic steatohepatitis will overwhelm the organ supply. Liver Transpl. 2014;20 Suppl 2:S32-S37. [PMID: 25155244 DOI: 10.1002/lt.23980] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
211 Piras IS, Gerhard GS, DiStefano JK. Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media. Cell Physiol Biochem 2020;54:1068-82. [PMID: 33095528 DOI: 10.33594/000000288] [Reference Citation Analysis]
212 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-40. [DOI: 10.1007/s00125-016-3902-y] [Cited by in Crossref: 206] [Cited by in F6Publishing: 166] [Article Influence: 41.2] [Reference Citation Analysis]
213 Bhatt BD, Lukose T, Siegel AB, Brown RS Jr, Verna EC. Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. J Gastrointest Oncol 2015;6:459-68. [PMID: 26487938 DOI: 10.3978/j.issn.2078-6891.2015.050] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
214 Huang X, Liu X, Yu Y. Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms? Front Mol Neurosci 2017;10:134. [PMID: 28533742 DOI: 10.3389/fnmol.2017.00134] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]
215 Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112:581-587. [PMID: 28195177 DOI: 10.1038/ajg.2017.5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 79] [Article Influence: 25.5] [Reference Citation Analysis]
216 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 50] [Article Influence: 20.3] [Reference Citation Analysis]
217 Gitto S, Falcini M, Marra F; MEDITRA Research Group. Metabolic Disorders After Liver Transplantation. Metab Syndr Relat Disord 2021;19:65-9. [PMID: 33104408 DOI: 10.1089/met.2020.0068] [Reference Citation Analysis]
218 Vusirikala A, Thomas T, Bhala N, Tahrani AA, Thomas GN, Nirantharakumar K. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN). BMC Endocr Disord 2020;20:96. [PMID: 32605642 DOI: 10.1186/s12902-020-00582-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
219 Durán-Vian C, Arias-Loste MT, Hernández JL, Fernández V, González M, Iruzubieta P, Rasines L, González-Vela C, Vaqué JP, Blanco R, Crespo J, González-López MA. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. J Eur Acad Dermatol Venereol 2019;33:2131-6. [PMID: 31260574 DOI: 10.1111/jdv.15764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
220 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci 2016;61:2108-17. [PMID: 26825843 DOI: 10.1007/s10620-016-4044-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
221 Safarian M, Mohammadpour S, Shafiee M, Ganji A, Soleimani A, Nematy M, Bahari A. Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosis. Diabetes Metab Syndr 2019;13:989-94. [PMID: 31336557 DOI: 10.1016/j.dsx.2019.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Gheflati A, Adelnia E, Nadjarzadeh A. The clinical effects of purslane ( Portulaca oleracea ) seeds on metabolic profiles in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. Phytotherapy Research 2019;33:1501-9. [DOI: 10.1002/ptr.6342] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
223 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 25.5] [Reference Citation Analysis]
224 Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013;52:175-191. [PMID: 23206728 DOI: 10.1016/j.plipres.2012.11.002] [Cited by in Crossref: 215] [Cited by in F6Publishing: 188] [Article Influence: 23.9] [Reference Citation Analysis]
225 Asrani SK, Hall L, Hagan M, Sharma S, Yeramaneni S, Trotter J, Talwalkar J, Kanwal F. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol 2019;114:98-106. [PMID: 30333543 DOI: 10.1038/s41395-018-0365-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
226 Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. Medicine (Baltimore). 2018;97:e11518. [PMID: 30075518 DOI: 10.1097/md.0000000000011518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
227 Cai C, Song X, Chen X, Zhou W, Jin Q, Chen S, Ji F. Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:8859338. [PMID: 33542909 DOI: 10.1155/2021/8859338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Tsochatzis E, Coilly A, Nadalin S, Levistky J, Tokat Y, Ghobrial M, Klinck J, Berenguer M. International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. Transplantation. 2019;103:45-56. [PMID: 30153225 DOI: 10.1097/tp.0000000000002433] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 15.5] [Reference Citation Analysis]
229 Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755-760. [PMID: 23370710 DOI: 10.1097/tp.0b013e31827afb3a] [Cited by in Crossref: 174] [Cited by in F6Publishing: 66] [Article Influence: 21.8] [Reference Citation Analysis]
230 Oseini AM, Cole BK, Issa D, Feaver RE, Sanyal AJ. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatol Int 2018;12:6-16. [PMID: 29299759 DOI: 10.1007/s12072-017-9838-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
231 Satapathy SK, Jiang Y, Eason JD, Kedia SK, Wong E, Singal AK, Tolley EA, Hathaway D, Nair S, Vanatta JM. Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States-a retrospective study. Transpl Int 2017;30:1051-60. [DOI: 10.1111/tri.13001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
232 Orman ES, Mayorga ME, Wheeler SB, Townsley RM, Toro-Diaz HH, Hayashi PH, Barritt AS 4th. Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transpl. 2015;21:1040-1050. [PMID: 25939487 DOI: 10.1002/lt.24160] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 11.6] [Reference Citation Analysis]
233 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
234 Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules 2017;22:E191. [PMID: 28125040 DOI: 10.3390/molecules22020191] [Cited by in Crossref: 132] [Cited by in F6Publishing: 94] [Article Influence: 33.0] [Reference Citation Analysis]
235 Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci. 2016;61:1294-1303. [PMID: 26841783 DOI: 10.1007/s10620-016-4049-x] [Cited by in Crossref: 164] [Cited by in F6Publishing: 144] [Article Influence: 32.8] [Reference Citation Analysis]
236 Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14:417-431. [PMID: 23387384 DOI: 10.1111/obr.12020] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 16.4] [Reference Citation Analysis]
237 Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia 2020;63:253-60. [PMID: 31713012 DOI: 10.1007/s00125-019-05024-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
238 Liebig M, Dannenberger D, Vollmar B, Abshagen K. n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model. Ther Adv Chronic Dis 2019;10:2040622319872118. [PMID: 31523414 DOI: 10.1177/2040622319872118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
239 Qi Y, Zhang Z, Liu S, Aluo Z, Zhang L, Yu L, Li Y, Song Z, Zhou L. Zinc Supplementation Alleviates Lipid and Glucose Metabolic Disorders Induced by a High-Fat Diet. J Agric Food Chem 2020;68:5189-200. [DOI: 10.1021/acs.jafc.0c01103] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
240 Vallet-Pichard A, Parlati L, Pol S. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health]. Presse Med 2019;48:1459-67. [PMID: 31757728 DOI: 10.1016/j.lpm.2019.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
241 Armstrong MJ, Hazlehurst JM, Hull D, Guo K, Borrows S, Yu J, Gough SC, Newsome PN, Tomlinson JW. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014;16:651-660. [PMID: 24962805 DOI: 10.1111/dom.12272] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
242 Crawford AR, Alamuddin N, Amaro A. Cardiometabolic Effects of Anti-obesity Pharmacotherapy. Curr Atheroscler Rep 2018;20:18. [PMID: 29511882 DOI: 10.1007/s11883-018-0719-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
243 Hernandez Roman J, Patel S. Why Do Lifestyle Recommendations Fail in Most Patients with Nonalcoholic Fatty Liver Disease? Gastroenterol Clin North Am 2020;49:95-104. [PMID: 32033766 DOI: 10.1016/j.gtc.2019.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Gariani K, Ryu D, Menzies KJ, Yi H, Stein S, Zhang H, Perino A, Lemos V, Katsyuba E, Jha P, Vijgen S, Rubbia-brandt L, Kim YK, Kim JT, Kim KS, Shong M, Schoonjans K, Auwerx J. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. Journal of Hepatology 2017;66:132-41. [DOI: 10.1016/j.jhep.2016.08.024] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 16.0] [Reference Citation Analysis]
245 Sharma S, Stine JG, Verbeek T, Bezinover D. Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00601-7. [PMID: 34391652 DOI: 10.1053/j.jvca.2021.07.020] [Reference Citation Analysis]
246 Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;37:720-729. [PMID: 23441892 DOI: 10.1111/apt.12255] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
247 Diaz-Nieto R, Lykoudis PM, Davidson BR. Recipient body mass index and infectious complications following liver transplantation. HPB (Oxford) 2019;21:1032-8. [PMID: 30713043 DOI: 10.1016/j.hpb.2019.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
248 Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Curr Vasc Pharmacol 2020;18:172-81. [PMID: 30961499 DOI: 10.2174/1570161117666190405164313] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
249 Kuo J, Serrano SS, Grönberg A, Massoumi R, Hansson MJ, Gallay P. Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis. Front Pharmacol 2019;10:1129. [PMID: 31611801 DOI: 10.3389/fphar.2019.01129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
250 Salameh H, Hanayneh MA, Masadeh M, Naseemuddin M, Matin T, Erwin A, Singal AK. PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum. J Clin Transl Hepatol. 2016;4:175-191. [PMID: 27777887 DOI: 10.14218/jcth.2016.00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
251 Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782-9.e4. [PMID: 23860502 DOI: 10.1053/j.gastro.2013.06.057] [Cited by in Crossref: 286] [Cited by in F6Publishing: 242] [Article Influence: 35.8] [Reference Citation Analysis]
252 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
253 Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis 2020;11:802. [PMID: 32978374 DOI: 10.1038/s41419-020-03003-w] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 26.0] [Reference Citation Analysis]
254 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
255 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. [DOI: 10.1002/hep.27368] [Cited by in Crossref: 1010] [Cited by in F6Publishing: 855] [Article Influence: 168.3] [Reference Citation Analysis]
256 Taneja S, Roy A. Nonalcoholic steatohepatitis recurrence after liver transplant. Transl Gastroenterol Hepatol 2020;5:24. [PMID: 32258528 DOI: 10.21037/tgh.2019.10.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
257 Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, Zarrinpar A, Petrowsky H, Farmer D, Yersiz H, Xia V, Hiatt JR, Busuttil RW. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg. 2012;256:624-633. [PMID: 22964732 DOI: 10.1097/sla.0b013e31826b4b7e] [Cited by in Crossref: 167] [Cited by in F6Publishing: 68] [Article Influence: 18.6] [Reference Citation Analysis]
258 Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, Thursz M, Lemoine M. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS 2019;33:805-14. [PMID: 30882489 DOI: 10.1097/QAD.0000000000002133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
259 Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis. 2012;16:631-645. [PMID: 22824485 DOI: 10.1016/j.cld.2012.05.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
260 Dobrindt EM, Allex L, Saipbaev A, Öllinger R, Schöning W, Pratschke J, Eurich D. Association between obesity after liver transplantation and steatosis, inflammation, and fibrosis of the graft. Clin Transplant 2020;34:e14093. [PMID: 32970896 DOI: 10.1111/ctr.14093] [Reference Citation Analysis]
261 Brouwers MCGJ, Simons N, Stehouwer CDA, Koek GH, Schaper NC, Isaacs A. Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease. Hepatol Commun 2019;3:587-96. [PMID: 30976747 DOI: 10.1002/hep4.1319] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
262 Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017;65:350-362. [PMID: 27358174 DOI: 10.1002/hep.28709] [Cited by in Crossref: 240] [Cited by in F6Publishing: 213] [Article Influence: 48.0] [Reference Citation Analysis]
263 Fox AN, Brown RS. Is the Patient a Candidate for Liver Transplantation? Clinics in Liver Disease 2012;16:435-48. [DOI: 10.1016/j.cld.2012.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
264 Lee SK, Yoon DW, Lee SW, Kim JY, Kim JK, Shin C. Non-alcoholic fatty liver disease among sasang constitutional types: a population-based study in Korea. BMC Complement Altern Med 2015;15:399. [PMID: 26547840 DOI: 10.1186/s12906-015-0925-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
265 Joo I, Lee JM, Yoon JH, Jang JJ, Han JK, Choi BI. Nonalcoholic fatty liver disease: intravoxel incoherent motion diffusion-weighted MR imaging-an experimental study in a rabbit model. Radiology. 2014;270:131-140. [PMID: 24091358 DOI: 10.1148/radiol.13122506] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
266 Verbeek J, Spincemaille P, Vanhorebeek I, Van den Berghe G, Vander Elst I, Windmolders P, van Pelt J, van der Merwe S, Bedossa P, Nevens F, Cammue B, Thevissen K, Cassiman D. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. Lipids Health Dis. 2017;16:46. [PMID: 28231800 DOI: 10.1186/s12944-017-0432-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
267 Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020;17:601-14. [PMID: 32984925 DOI: 10.1007/s11904-020-00531-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int 2016;36:1563-79. [DOI: 10.1111/liv.13185] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 17.0] [Reference Citation Analysis]
269 Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT, Kohli DR, Matherly S, Puri P, Gilles H, Cotterell A, Levy M, Sterling RK, Luketic VA, Lee H, Sharma A, Siddiqui MS. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. Transplantation. 2017;101:1867-1874. [PMID: 28296807 DOI: 10.1097/tp.0000000000001709] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 16.3] [Reference Citation Analysis]
270 Yang W, Jiang C, Wang Z, Zhang J, Mao X, Chen G, Yao X, Liu C. Cyclocarya paliurus extract attenuates hepatic lipid deposition in HepG2 cells by the lipophagy pathway. Pharmaceutical Biology 2020;58:838-44. [DOI: 10.1080/13880209.2020.1803365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
271 Parente DB, Rodrigues RS, Paiva FF, Oliveira Neto JA, Machado-Silva L, Lanzoni V, Campos CF, Eiras-Araujo AL, do Brasil PE, Garteiser P, Gomes MB, de Mello Perez R. Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One 2014;9:e112574. [PMID: 25426708 DOI: 10.1371/journal.pone.0112574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
272 Safwan M, Collins KM, Abouljoud MS, Salgia R. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl. 2017;23:1415-1421. [PMID: 28752920 DOI: 10.1002/lt.24832] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
273 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 16.8] [Reference Citation Analysis]
274 Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Ther 2014;40:938-48. [DOI: 10.1111/apt.12912] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
275 Perito ER, Rodriguez LA, Lustig RH. Dietary treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2013;29:170-6. [PMID: 23283181 DOI: 10.1097/MOG.0b013e32835ca11d] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
276 Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol. 2014;20:7366-7380. [PMID: 24966607 DOI: 10.3748/wjg.v20.i23.7366] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 72] [Article Influence: 14.2] [Reference Citation Analysis]
277 Ivanics T, Abreu P, De Martin E, Sapisochin G. Changing Trends in Liver Transplantation: Challenges and Solutions. Transplantation 2021;105:743-56. [PMID: 32910093 DOI: 10.1097/TP.0000000000003454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
278 Loomba R, Jain A, Diehl AM, Guy CD, Portenier D, Sudan R, Singh S, Faulkner C, Richards L, Hester KD, Okada L, Li XJ, Mimms L, Abdelmalek MF. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2019;17:1867-1876.e3. [PMID: 30448594 DOI: 10.1016/j.cgh.2018.11.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
279 Loy VM, Joyce C, Bello S, Vonroenn N, Cotler SJ. Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis. Clin Transplant 2018;32:e13297. [DOI: 10.1111/ctr.13297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Adv Ther 2017;34:2120-38. [PMID: 28808886 DOI: 10.1007/s12325-017-0601-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
281 Cotter TG, Charlton M. Nonalcoholic Steatohepatitis After Liver Transplantation. Liver Transpl 2019;26:141-59. [DOI: 10.1002/lt.25657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
282 Merola J, Liapakis A, Mulligan DC, Yoo PS. Non-alcoholic fatty liver disease following liver transplantation: a clinical review. Clin Transplant 2015;29:728-37. [PMID: 26147308 DOI: 10.1111/ctr.12585] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
283 Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37 Suppl 1:97-103. [PMID: 28052626 DOI: 10.1111/liv.13302] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 26.8] [Reference Citation Analysis]
284 Ivanics T, Shwaartz C, Claasen MPAW, Patel MS, Yoon P, Raschzok N, Wallace D, Muaddi H, Murillo Perez CF, Hansen BE, Selzner N, Sapisochin G. Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. Transpl Int 2021;34:1444-54. [PMID: 33977568 DOI: 10.1111/tri.13903] [Reference Citation Analysis]
285 Zhou J, Hu Z, Zhang Q, Li Z, Xiang J, Yan S, Wu J, Zhang M, Zheng S. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database. PLoS One. 2016;11:e0155179. [PMID: 27171501 DOI: 10.1371/journal.pone.0155179] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
286 Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, Pender J, Pomp A, Roerig J, Machado LL, Wolfe BM, Belle SH; LABS Consortium. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 2014;34:98-107. [PMID: 24782263 DOI: 10.1055/s-0034-1371083] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
287 Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond) 2018;18:245-50. [PMID: 29858436 DOI: 10.7861/clinmedicine.18-3-245] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
288 Beal EW, Tumin D, Conteh LF, Hanje AJ, Michaels AJ, Hayes D Jr, Black SM, Mumtaz K. Impact of Recipient and Donor Obesity Match on the Outcomes of Liver Transplantation: All Matches Are Not Perfect. J Transplant 2016;2016:9709430. [PMID: 27688905 DOI: 10.1155/2016/9709430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
289 Pankowicz FP, Barzi M, Legras X, Hubert L, Mi T, Tomolonis JA, Ravishankar M, Sun Q, Yang D, Borowiak M, Sumazin P, Elsea SH, Bissig-Choisat B, Bissig KD. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun 2016;7:12642. [PMID: 27572891 DOI: 10.1038/ncomms12642] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 14.4] [Reference Citation Analysis]
290 Andrade AR, Bittencourt PL, Codes L, Evangelista MA, Castro AO, Sorte NB, Almeida CG, Bastos JA, Cotrim HP. New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation. Annals of Hepatology 2017;16:932-40. [DOI: 10.5604/01.3001.0010.5285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
291 Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology 2012;56:2172-9. [PMID: 22707355 DOI: 10.1002/hep.25887] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
292 Patel YA, Berg CL, Moylan CA. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Dig Dis Sci. 2016;61:1406-1416. [PMID: 26815171 DOI: 10.1007/s10620-016-4035-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 7.6] [Reference Citation Analysis]
293 Benbow JH, Thompson KJ, Cope HL, Brandon-Warner E, Culberson CR, Bossi KL, Li T, Russo MW, Gersin KS, McKillop IH, deLemos AS, Schrum LW. Diet-Induced Obesity Enhances Progression of Hepatocellular Carcinoma through Tenascin-C/Toll-Like Receptor 4 Signaling. Am J Pathol. 2016;186:145-158. [PMID: 26603137 DOI: 10.1016/j.ajpath.2015.09.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
294 De Chiara F, Ureta Checcllo C, Ramón Azcón J. High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths. Nutrients 2019;11:E2985. [PMID: 31817648 DOI: 10.3390/nu11122985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
295 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007-1019. [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021] [Cited by in Crossref: 237] [Cited by in F6Publishing: 184] [Article Influence: 26.3] [Reference Citation Analysis]
296 Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 2016;387:679-90. [DOI: 10.1016/s0140-6736(15)00803-x] [Cited by in Crossref: 762] [Cited by in F6Publishing: 290] [Article Influence: 152.4] [Reference Citation Analysis]
297 Hobeika C, Ronot M, Beaufrere A, Paradis V, Soubrane O, Cauchy F. Metabolic syndrome and hepatic surgery. J Visc Surg 2020;157:231-8. [PMID: 31866269 DOI: 10.1016/j.jviscsurg.2019.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
298 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
299 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
300 Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, Alhaddad R, Alkhouri N. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9. [DOI: 10.1007/s12072-015-9679-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 10.3] [Reference Citation Analysis]
301 Fayek SA, Quintini C, Chavin KD, Marsh CL. The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council. Am J Transplant 2016;16:3093-104. [PMID: 27545282 DOI: 10.1111/ajt.14017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 39] [Article Influence: 11.4] [Reference Citation Analysis]
302 Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, Ikhwan MA, Bassirian S, Cepin S, Gonzalez MP, Mendler M, Kono Y, Vodkin I, Mekeel K, Haldorson J, Hemming A, Andrews B, Salotti J, Richards L, Brenner DA, Sirlin CB, Loomba R; Familial NAFLD Cirrhosis Research Consortium. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127:2697-704. [PMID: 28628033 DOI: 10.1172/JCI93465] [Cited by in Crossref: 72] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
303 Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology 2016;14:5-12. [DOI: 10.1016/j.cgh.2015.05.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 10.4] [Reference Citation Analysis]
304 Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: Does sex matter? J Hepatol. 2015;62:946-955. [PMID: 25433162 DOI: 10.1016/j.jhep.2014.11.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
305 Li L, Fu J, Sun J, Liu D, Chen C, Wang H, Hou Y, Xu Y, Pi J. Is Nrf2-ARE a potential target in NAFLD mitigation? Current Opinion in Toxicology 2019;13:35-44. [DOI: 10.1016/j.cotox.2018.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
306 VanWagner LB, Serper M, Kang R, Levitsky J, Hohmann S, Abecassis M, Skaro A, Lloyd-Jones DM. Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. Am J Transplant. 2016;16:2684-2694. [PMID: 26946333 DOI: 10.1111/ajt.13779] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 16.6] [Reference Citation Analysis]
307 Liang T, Alloosh M, Bell LN, Fullenkamp A, Saxena R, Van Alstine W, Bybee P, Werling K, Sturek M, Chalasani N. Liver injury and fibrosis induced by dietary challenge in the Ossabaw miniature Swine. PLoS One. 2015;10:e0124173. [PMID: 25978364 DOI: 10.1371/journal.pone.0046526] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
308 McGettigan BM, McMahan RH, Luo Y, Wang XX, Orlicky DJ, Porsche C, Levi M, Rosen HR. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease. J Biol Chem 2016;291:23058-67. [PMID: 27605663 DOI: 10.1074/jbc.M116.731042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
309 Musolino V, Gliozzi M, Scarano F, Bosco F, Scicchitano M, Nucera S, Carresi C, Ruga S, Zito MC, Maiuolo J, Macrì R, Amodio N, Juli G, Tassone P, Mollace R, Caffrey R, Marioneaux J, Walker R, Ehrlich J, Palma E, Muscoli C, Bedossa P, Salvemini D, Mollace V, Sanyal AJ. Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. Sci Rep 2020;10:2565. [PMID: 32054943 DOI: 10.1038/s41598-020-59485-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
310 Nickel F, Tapking C, Benner L, Sollors J, Billeter AT, Kenngott HG, Bokhary L, Schmid M, von Frankenberg M, Fischer L. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study. Obes Surg. 2018;28:1342-1350. [PMID: 29119336 DOI: 10.1007/s11695-017-3012-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 22.5] [Reference Citation Analysis]
311 Carr RM, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am 2016;45:639-52. [PMID: 27837778 DOI: 10.1016/j.gtc.2016.07.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 68] [Article Influence: 17.8] [Reference Citation Analysis]
312 Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2012;46:457-467. [PMID: 22469640 DOI: 10.1097/mcg.0b013e31824cf51e] [Cited by in Crossref: 64] [Cited by in F6Publishing: 29] [Article Influence: 7.1] [Reference Citation Analysis]
313 Malhi H, Allen AM, Watt KD. Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival. Curr Opin Organ Transplant. 2016;21:99-106. [PMID: 26825357 DOI: 10.1097/mot.0000000000000283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
314 Lv Y, Patel N, Zhang HJ. The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer. Expert Rev Gastroenterol Hepatol 2019;13:1169-80. [PMID: 31774328 DOI: 10.1080/17474124.2019.1697231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
315 Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19:8301-8311. [PMID: 24363521 DOI: 10.3748/wjg.v19.i45.8301] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
316 Colgan TJ, Van Pay AJ, Sharma SD, Mao L, Reeder SB. Diurnal Variation of Proton Density Fat Fraction in the Liver Using Quantitative Chemical Shift Encoded MRI. J Magn Reson Imaging 2020;51:407-14. [PMID: 31168893 DOI: 10.1002/jmri.26814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Kim BM, Abdelfattah AM, Vasan R, Fuchs BC, Choi MY. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis. Sci Rep 2018;8:7499. [PMID: 29760499 DOI: 10.1038/s41598-018-25699-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
318 Leite NC, Villela-Nogueira CA, Ferreira MT, Cardoso CR, Salles GF. Increasing aortic stiffness is predictive of advanced liver fibrosis in patients with type 2 diabetes: the Rio-T2DM cohort study. Liver Int. 2016;36:977-985. [PMID: 26509555 DOI: 10.1111/liv.12994] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
319 Siddiqui MS, Charlton M. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology 2016;150:1849-62. [DOI: 10.1053/j.gastro.2016.02.077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
320 Sarkar M, Wellons M, Cedars MI, VanWagner L, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, Terrault N. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol 2017;112:755-62. [PMID: 28291240 DOI: 10.1038/ajg.2017.44] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
321 DiStefano JK. Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. Cell Mol Life Sci 2020;77:2079-90. [PMID: 31760464 DOI: 10.1007/s00018-019-03390-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
322 von Wulffen M, Clark PJ, Macdonald GA, Raj AS, Kendall BJ, Powell EE, Jones MP, Holtmann G. Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. Aliment Pharmacol Ther 2016;44:68-77. [PMID: 27189900 DOI: 10.1111/apt.13657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
323 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol. 2014;6:263-273. [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
324 Amin RF, El Bendary AS, Ezzat SE, Mohamed WS. Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients. Diabetes Metab Syndr 2019;13:2226-9. [PMID: 31235161 DOI: 10.1016/j.dsx.2019.05.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
325 Smith JD, Fu E, Kobayashi MA. Prevention and Management of Childhood Obesity and Its Psychological and Health Comorbidities. Annu Rev Clin Psychol 2020;16:351-78. [PMID: 32097572 DOI: 10.1146/annurev-clinpsy-100219-060201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
326 Graziadei I, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, Müller H, Kohl C, Sperner-Unterweger B, Eschertzhuber S, Hofer H, Öfner D, Tilg H, Vogel W, Trauner M, Berlakovich G. Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016;128:679-90. [PMID: 27590261 DOI: 10.1007/s00508-016-1046-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
327 Herrema H, Zhou Y, Zhang D, Lee J, Salazar Hernandez MA, Shulman GI, Ozcan U. XBP1s Is an Anti-lipogenic Protein. J Biol Chem 2016;291:17394-404. [PMID: 27325692 DOI: 10.1074/jbc.M116.728949] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 8.6] [Reference Citation Analysis]
328 Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2018;22:11-21. [PMID: 29128051 DOI: 10.1016/j.cld.2017.08.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 62] [Article Influence: 26.3] [Reference Citation Analysis]
329 Jiang X, Jiang L, Shan A, Su Y, Cheng Y, Song D, Ji H, Ning G, Wang W, Cao Y. Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice. EBioMedicine 2018;37:307-21. [PMID: 30316865 DOI: 10.1016/j.ebiom.2018.09.051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
330 Vonghia L, Van Herck MA, Weyler J, Francque S. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease. Front Immunol 2019;10:563. [PMID: 30972062 DOI: 10.3389/fimmu.2019.00563] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
331 Jiménez-Pérez M, González-Grande R, Omonte Guzmán E, Amo Trillo V, Rodrigo López JM. Metabolic complications in liver transplant recipients. World J Gastroenterol 2016;22:6416-23. [PMID: 27605877 DOI: 10.3748/wjg.v22.i28.6416] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
332 Gitto S, Vukotic R, Vitale G, Pirillo M, Villa E, Andreone P. Non-alcoholic steatohepatitis and liver transplantation. Dig Liver Dis. 2016;48:587-591. [PMID: 27038703 DOI: 10.1016/j.dld.2016.02.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
333 Yen YH, Chen JF, Wu CK, Lin MT, Chang KC, Tseng PL, Tsai MC, Lin JT, Hu TH. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. J Formos Med Assoc 2017;116:852-61. [PMID: 28888355 DOI: 10.1016/j.jfma.2017.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
334 Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2019;156:88-95.e5. [PMID: 30222962 DOI: 10.1053/j.gastro.2018.09.021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
335 Jahn D, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's point of view. Biochim Biophys Acta Mol Basis Dis 2019;1865:943-53. [PMID: 29990551 DOI: 10.1016/j.bbadis.2018.06.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
336 Khullar V, Dolganiuc A, Firpi RJ. Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant 2014;4:81-92. [PMID: 25032097 DOI: 10.5500/wjt.v4.i2.81] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
337 Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, Kava J, Bynevelt M, MacQuillan GC, Garas G, Ayonrinde OT, Mori TA, Croft KD, Niu X, Jeffrey GP, Olynyk JK. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology. 2015;61:1555-1564. [PMID: 25524401 DOI: 10.1002/hep.27662] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
338 Pockros PJ, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz EJ, Hellstern PA, Owens-Grillo J, Van Biene C, Shringarpure R, MacConell L, Shapiro D, Cohen DE. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int 2019;39:2082-93. [PMID: 31402538 DOI: 10.1111/liv.14209] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
339 Harlow KE, Africa JA, Wells A, Belt PH, Behling CA, Jain AK, Molleston JP, Newton KP, Rosenthal P, Vos MB, Xanthakos SA, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2018;198:76-83.e2. [PMID: 29661561 DOI: 10.1016/j.jpeds.2018.02.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
340 Goh GB, Issa D, Lopez R, Dasarathy S, Dasarathy J, Sargent R, Hawkins C, Pai RK, Yerian L, Khiyami A. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:995-1000. [PMID: 26589761 DOI: 10.1111/jgh.13235] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
341 Liu M, Liu S, Shang M, Liu X, Wang Y, Li Q, Mambiya M, Yang L, Zhang Q, Zhang K, Nie F, Zeng F, Liu W. Association between ADIPOQ G276T and C11377G polymorphisms and the risk of non-alcoholic fatty liver disease: An updated meta-analysis. Mol Genet Genomic Med 2019;7:e624. [PMID: 30838812 DOI: 10.1002/mgg3.624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
342 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
343 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai R, McCullough AJ, Dasarathy S. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 2015;35:979-985. [PMID: 24905085 DOI: 10.1111/liv.12611] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
344 He W, An X, Li L, Shao X, Li Q, Yao Q, Zhang JA. Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Front Endocrinol (Lausanne) 2017;8:335. [PMID: 29238323 DOI: 10.3389/fendo.2017.00335] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
345 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 151] [Article Influence: 60.3] [Reference Citation Analysis]
346 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
347 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 138] [Cited by in F6Publishing: 105] [Article Influence: 46.0] [Reference Citation Analysis]
348 Baker S, Chambers C, McQuillan P, Janicki P, Kadry Z, Bowen D, Bezinover D. Myocardial perfusion imaging is an effective screening test for coronary artery disease in liver transplant candidates. Clin Transplant. 2015;29:319-326. [PMID: 25604507 DOI: 10.1111/ctr.12517] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
349 Xanthakos SA, Crimmins NA, Chernausek SD. Abnormalities in the growth hormone axis and risk of nonalcoholic steatohepatitis: active player or innocent bystander? J Pediatr 2014;165:12-4. [PMID: 24793205 DOI: 10.1016/j.jpeds.2014.03.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
350 Song M, Li X, Zhang X, Shi H, Vos MB, Wei X, Wang Y, Gao H, Rouchka EC, Yin X, Zhou Z, Prough RA, Cave MC, McClain CJ. Dietary copper-fructose interactions alter gut microbial activity in male rats. Am J Physiol Gastrointest Liver Physiol 2018;314:G119-30. [PMID: 29025734 DOI: 10.1152/ajpgi.00378.2016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
351 Roth CG, Marzio DH, Guglielmo FF. Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs. Dig Dis Sci 2018;63:1102-22. [PMID: 29549474 DOI: 10.1007/s10620-018-4991-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
352 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
353 Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014;20:5320-5330. [PMID: 24833862 DOI: 10.3748/wjg.v20.i18.5320] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
354 Dooghaie Moghadam A, Eslami P, Razavi-Khorasani N, Moazzami B, Zahedi-Tajrishi F, Farokhi E, Makhdoomi Sharabiani K, Mansour-Ghanaei A, Mehrvar A, Aghajanpoor Pasha M, Saeedi S, Iravani S. Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. Caspian J Intern Med 2020;11:346-54. [PMID: 33680375 DOI: 10.22088/cjim.11.4.346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
355 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 90] [Article Influence: 28.8] [Reference Citation Analysis]
356 Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol. 2017;9:385-390. [PMID: 28321274 DOI: 10.4254/wjh.v9.i7.385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
357 Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson LMS, Fargion S, Romeo S, Kozlitina J, Valenti L. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med 2018;283:356-70. [PMID: 29280273 DOI: 10.1111/joim.12719] [Cited by in Crossref: 121] [Cited by in F6Publishing: 101] [Article Influence: 30.3] [Reference Citation Analysis]
358 Holmer M, Melum E, Isoniemi H, Ericzon BG, Castedal M, Nordin A, Aagaard Schultz N, Rasmussen A, Line PD, Stål P, Bennet W, Hagström H. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver Int 2018;38:2082-90. [PMID: 29630771 DOI: 10.1111/liv.13751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
359 Sauerbeck AD, Laws JL, Bandaru VV, Popovich PG, Haughey NJ, McTigue DM. Spinal cord injury causes chronic liver pathology in rats. J Neurotrauma 2015;32:159-69. [PMID: 25036371 DOI: 10.1089/neu.2014.3497] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
360 Liu X, Chen S, Zhang L. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2020;319:E34-42. [PMID: 32228319 DOI: 10.1152/ajpendo.00528.2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
361 Nissar AU, Sharma L, Tasduq SA. Palmitic acid induced lipotoxicity is associated with altered lipid metabolism, enhanced CYP450 2E1 and intracellular calcium mediated ER stress in human hepatoma cells. Toxicol Res 2015;4:1344-58. [DOI: 10.1039/c5tx00101c] [Cited by in Crossref: 12] [Article Influence: 2.0] [Reference Citation Analysis]
362 Koo SH, Chu CW, Khoo JJC, Cheong M, Soon GH, Ho EXP, Law NM, De Sessions PF, Fock KM, Ang TL, Lee EJD, Hsiang JC. A pilot study to examine the association between human gut microbiota and the host's central obesity. JGH Open 2019;3:480-7. [PMID: 31832548 DOI: 10.1002/jgh3.12184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
363 Jeyapal S, Kona SR, Mullapudi SV, Putcha UK, Gurumurthy P, Ibrahim A. Substitution of linoleic acid with α-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis. Sci Rep 2018;8:10953. [PMID: 30026586 DOI: 10.1038/s41598-018-29222-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
364 Liang T, Alloosh M, Bell LN, Fullenkamp A, Saxena R, Van Alstine W, Bybee P, Werling K, Sturek M, Chalasani N, Masuoka HC. Liver injury and fibrosis induced by dietary challenge in the Ossabaw miniature Swine. PLoS One 2015;10:e0124173. [PMID: 25978364 DOI: 10.1371/journal.pone.0124173] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
365 Zhang Q, Zhao Y, Wu J, Xie L, Chen A, Liu Y, Song Q, Li J, Wu T, Xie L, Liu A. Quantification of Hepatic Fat Fraction in Patients With Nonalcoholic Fatty Liver Disease: Comparison of Multimaterial Decomposition Algorithm and Fat (Water)-Based Material Decomposition Algorithm Using Single-Source Dual-Energy Computed Tomography. J Comput Assist Tomogr 2021;45:12-7. [PMID: 33186174 DOI: 10.1097/RCT.0000000000001112] [Reference Citation Analysis]
366 Povero D, Yamashita H, Ren W, Subramanian MG, Myers RP, Eguchi A, Simonetto DA, Goodman ZD, Harrison SA, Sanyal AJ, Bosch J, Feldstein AE. Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. Hepatol Commun 2020;4:1263-78. [PMID: 32923831 DOI: 10.1002/hep4.1556] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
367 Jia X, Zhai T. Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2019;10:599. [PMID: 31551930 DOI: 10.3389/fendo.2019.00599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
368 Asrani SK, Kouznetsova M, Ogola G, Taylor T, Masica A, Pope B, Trotter J, Kamath P, Kanwal F. Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. Gastroenterology. 2018;155:719-729.e4. [PMID: 29802851 DOI: 10.1053/j.gastro.2018.05.032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
369 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
370 Kalavalapalli S, Bril F, Guingab J, Vergara A, Garrett TJ, Sunny NE, Cusi K. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. J Endocrinol. 2019;241:293-305. [PMID: 31082799 DOI: 10.1530/joe-19-0007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
371 Van der Graaff D, Kwanten WJ, Couturier FJ, Govaerts JS, Verlinden W, Brosius I, D'Hondt M, Driessen A, De Winter BY, De Man JG, Michielsen PP, Francque SM. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. Lab Invest 2018;98:1263-75. [PMID: 29326427 DOI: 10.1038/s41374-017-0018-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
372 Van Herck J, Verbeek J, van Malenstein H, Laleman W, Cassiman D, Verslype C, van der Merwe S, Jochmans I, Sainz-Barriga M, Monbaliu D, Pirenne J, Nevens F. Liver-Related and Cardiovascular Outcome of Patients Transplanted for Nonalcoholic Fatty Liver Disease: A European Single-Center Study. Transplant Proc 2021;53:1674-81. [PMID: 34016462 DOI: 10.1016/j.transproceed.2021.02.025] [Reference Citation Analysis]
373 Siddiqui MB, Patel S, Bhati C, Reichman T, Williams K, Driscoll C, Liptrap E, Rinella ME, Sterling RK, Siddiqui MS. Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplant Proc 2019;51:1895-901. [PMID: 31399173 DOI: 10.1016/j.transproceed.2019.04.062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
374 Imajo K, Kessoku T, Honda Y, Hasegawa S, Tomeno W, Ogawa Y, Motosugi U, Saigusa Y, Yoneda M, Kirikoshi H, Yamanaka S, Utsunomiya D, Saito S, Nakajima A. MRI-Based Quantitative R2* Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients. J Magn Reson Imaging 2021. [PMID: 34184822 DOI: 10.1002/jmri.27810] [Reference Citation Analysis]
375 Alkhouri N, Hanouneh IA, Zein NN, Lopez R, Kelly D, Eghtesad B, Fung JJ. Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int. 2016;29:418-424. [PMID: 26402655 DOI: 10.1111/tri.12694] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
376 García-Monzón C, Vargas-Castrillón J, Porrero JL, Alonso MT, Bonachía O, Castillo MJ, Marcos A, Quirós E, Ramos B, Sánchez-Cabezudo C, Villar S, Sáez A, Rodríguez de Cía J, del Pozo E, Vega-Piris L, Soto-Fernández S, Lo Iacono O, Miquilena-Colina ME. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. Liver Int 2015;35:1983-91. [PMID: 25708133 DOI: 10.1111/liv.12813] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
377 Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32:22-29. [PMID: 22418885 DOI: 10.1055/s-0032-1306423] [Cited by in Crossref: 122] [Cited by in F6Publishing: 104] [Article Influence: 13.6] [Reference Citation Analysis]
378 Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64:638-652. [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 89] [Article Influence: 14.9] [Reference Citation Analysis]
379 Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. J Acquir Immune Defic Syndr 2019;80:e86-94. [PMID: 30570529 DOI: 10.1097/QAI.0000000000001936] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
380 VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015;35:2575-2583. [PMID: 25977117 DOI: 10.1111/liv.12872] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
381 Wong CR, Nguyen MH, Lim JK. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2016;22:8294-303. [PMID: 27729736 DOI: 10.3748/wjg.v22.i37.8294] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
382 Robinson A, Tavakoli H, Liu B, Bhuket T, Wong RJ. Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening. Hepatol Commun 2018;2:1147-55. [PMID: 30202827 DOI: 10.1002/hep4.1236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
383 Hsiang JC, Bai WW, Raos Z, Stableforth W, Upton A, Selvaratnam S, Gane EJ, Gerred SJ. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand: Cirrhosis outcomes in New Zealand. Intern Med J 2015;45:160-9. [DOI: 10.1111/imj.12624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
384 Ganschow R, Pollok JM, Jankofsky M, Junge G. The role of everolimus in liver transplantation. Clin Exp Gastroenterol. 2014;7:329-343. [PMID: 25214801 DOI: 10.2147/ceg.s41780] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
385 Kutsenko A, Ladenheim MR, Kim N, Nguyen P, Chen V, Jayasekera C, Yang JD, Kumari R, Roberts L, Nguyen MH. Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2017;51:384-90. [DOI: 10.1097/mcg.0000000000000689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
386 Hegyi PJ, Soós A, Hegyi P, Szakács Z, Hanák L, Váncsa S, Ocskay K, Pétervári E, Balaskó M, Eröss B, Pár G. Pre-transplant Sarcopenic Obesity Worsens the Survival After Liver Transplantation: A Meta-Analysis and a Systematic Review. Front Med (Lausanne) 2020;7:599434. [PMID: 33392221 DOI: 10.3389/fmed.2020.599434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
387 Adkins Y, Schie IW, Fedor D, Reddy A, Nguyen S, Zhou P, Kelley DS, Wu J. A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance. Lab Invest 2013;93:1313-22. [PMID: 24145238 DOI: 10.1038/labinvest.2013.123] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
388 Jang E, Shin MH, Kim KS, Kim Y, Na YC, Woo HJ, Kim Y, Lee JH, Jang HJ. Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells. BMC Complement Altern Med 2014;14:253. [PMID: 25038800 DOI: 10.1186/1472-6882-14-253] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
389 Orloff MS, Dokus MK. It is more than just size: Obesity and transplantation: Editorial. Liver Transpl 2013;19:790-5. [DOI: 10.1002/lt.23705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
390 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020;12:1168-81. [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
391 Singh A, Garg R, Lan N, Siddiqui MT, Gupta M, Alkhouri N. Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:591-8. [DOI: 10.1007/s12664-020-01087-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
392 Heimbach JK, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, Hay JE, Wiesner RH, Sanchez W, Rosen CB, Swain JM. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013;13:363-368. [PMID: 23137119 DOI: 10.1111/j.1600-6143.2012.04318.x] [Cited by in Crossref: 167] [Cited by in F6Publishing: 117] [Article Influence: 18.6] [Reference Citation Analysis]
393 Alkhouri N, Poordad F, Lawitz E. Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes. Hepatol Commun. 2018;2:778-785. [PMID: 30027137 DOI: 10.1002/hep4.1195] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
394 Satapathy SK, Banerjee P, Pierre JF, Higgins D, Dutta S, Heda R, Khan SD, Mupparaju VK, Mas V, Nair S, Eason JD, Kleiner DE, Maluf DG. Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplant Direct 2020;6:e625. [PMID: 33204823 DOI: 10.1097/TXD.0000000000001033] [Reference Citation Analysis]
395 Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology 2015;148:547-55. [DOI: 10.1053/j.gastro.2014.11.039] [Cited by in Crossref: 970] [Cited by in F6Publishing: 800] [Article Influence: 161.7] [Reference Citation Analysis]
396 Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res. 2015;77:245-251. [PMID: 25310763 DOI: 10.1038/pr.2014.157] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 10.4] [Reference Citation Analysis]
397 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 49.0] [Reference Citation Analysis]
398 Machado MV, Cortez-pinto H. Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment? Liver Int 2014;34:1291-4. [DOI: 10.1111/liv.12578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
399 Wang S, Toy M, Hang Pham TT, So S. Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019. PLoS One 2020;15:e0239393. [PMID: 32946502 DOI: 10.1371/journal.pone.0239393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
400 Carr RM, Correnti J. Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci. 2015;1353:1-20. [PMID: 25998863 DOI: 10.1111/nyas.12787] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
401 Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterol. 2015;15:175. [PMID: 26666336 DOI: 10.1186/s12876-015-0407-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
402 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 14.7] [Reference Citation Analysis]
403 Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58. [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011] [Cited by in Crossref: 156] [Cited by in F6Publishing: 137] [Article Influence: 17.3] [Reference Citation Analysis]
404 Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012;16:487-504. [PMID: 22824477 DOI: 10.1016/j.cld.2012.05.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
405 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Huang Y, Wan T, Pang N, Zhou Y, Jiang X, Li B, Gu Y, Huang Y, Ye X, Lian H, Zhang Z, Yang L. Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high‐fat high cholesterol diet via regulating NF‐κB and NLRP3 inflammasome pathway. J Cell Physiol 2019;234:21224-34. [DOI: 10.1002/jcp.28728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
407 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
408 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 1478] [Cited by in F6Publishing: 1237] [Article Influence: 295.6] [Reference Citation Analysis]
409 Liu Z, Suo C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00379-0. [PMID: 34348882 DOI: 10.1016/j.dld.2021.07.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Hoodeshenas S, Yin M, Venkatesh SK. Magnetic Resonance Elastography of Liver: Current Update. Top Magn Reson Imaging. 2018;27:319-333. [PMID: 30289828 DOI: 10.1097/rmr.0000000000000177] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 19.5] [Reference Citation Analysis]
411 Graziadei I. [Intensive care treatment before and after liver transplantation]. Med Klin Intensivmed Notfmed 2014;109:411-7. [PMID: 25142222 DOI: 10.1007/s00063-014-0364-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
412 Ayloo S, Armstrong J, Hurton S, Molinari M. Obesity and liver transplantation. World J Transplant. 2015;5:95-101. [PMID: 26421262 DOI: 10.5500/wjt.v5.i3.95] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
413 Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 2016;65:1172-82. [DOI: 10.1016/j.metabol.2015.10.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
414 Matsumoto T, Takami T, Sakaida I. Cell transplantation as a non-invasive strategy for treating liver fibrosis. Expert Rev Gastroenterol Hepatol 2016;10:639-48. [PMID: 26691057 DOI: 10.1586/17474124.2016.1134313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
415 Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, Yang HI, Su CW, Lin HC, Lee FY, Wu JC, Lee SD. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One 2015;10:e0120443. [PMID: 25781622 DOI: 10.1371/journal.pone.0120443] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
416 Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:1226-33. [PMID: 27003142 DOI: 10.1007/s10620-016-4095-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 13.4] [Reference Citation Analysis]
417 Olson JC. Acute-on-chronic and Decompensated Chronic Liver Failure: Definitions, Epidemiology, and Prognostication. Crit Care Clin 2016;32:301-9. [PMID: 27339672 DOI: 10.1016/j.ccc.2016.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
418 Saki S, Saki N, Poustchi H, Malekzadeh R. Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events. Middle East J Dig Dis 2020;12:65-88. [PMID: 32626560 DOI: 10.34172/mejdd.2020.166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017;31:1621-1632. [PMID: 28398960 DOI: 10.1097/qad.0000000000001504] [Cited by in Crossref: 79] [Cited by in F6Publishing: 29] [Article Influence: 26.3] [Reference Citation Analysis]
420 Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N. Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. Journal of Clinical Gastroenterology 2018;52:339-46. [DOI: 10.1097/mcg.0000000000000925] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 15.7] [Reference Citation Analysis]
421 Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M, Ghali P. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015;10:e0128774. [PMID: 26083565 DOI: 10.1371/journal.pone.0128774] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
422 Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers MCGJ. PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. Gastroenterology 2017;152:912-3. [PMID: 28157516 DOI: 10.1053/j.gastro.2016.12.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
423 Fukui N, Golabi P, Otgonsuren M, de Avila L, Bush H, Younossi Z. Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. Aliment Pharmacol Ther 2018;47:680-8. [DOI: 10.1111/apt.14484] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
424 Gopal T, Kumar N, Perriotte-Olson C, Casey CA, Donohue TM Jr, Harris EN, Talmon G, Kabanov AV, Saraswathi V. Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver. Am J Physiol Gastrointest Liver Physiol. 2020;318:G428-G438. [PMID: 31928222 DOI: 10.1152/ajpgi.00217.2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
425 Sharpton SR, Terrault NA, Tavakol MM, Posselt AM. Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing posttransplant metabolic complications. Am J Transplant 2021. [PMID: 33780129 DOI: 10.1111/ajt.16583] [Reference Citation Analysis]
426 Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radic Res. 2015;49:1405-1418. [PMID: 26223319 DOI: 10.3109/10715762.2015.1078461] [Cited by in Crossref: 145] [Cited by in F6Publishing: 128] [Article Influence: 24.2] [Reference Citation Analysis]
427 Torres JL, Novo-Veleiro I, Manzanedo L, Alvela-Suárez L, Macías R, Laso FJ, Marcos M. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J Gastroenterol 2018;24:4104-18. [PMID: 30271077 DOI: 10.3748/wjg.v24.i36.4104] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
428 Wieland AC, Quallick M, Truesdale A, Mettler P, Bambha KM. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58:2809-2816. [PMID: 23843097 DOI: 10.1007/s10620-013-2740-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
429 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia: Burden of fatty liver in Australia. Journal of Gastroenterology and Hepatology 2018;33:1-11. [DOI: 10.1111/jgh.14270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
430 Wattacheril J, Chalasani N. Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology 2012;56:1580-4. [PMID: 23038652 DOI: 10.1002/hep.26031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
431 Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Sobocan N, Stimac D, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol. 2018;24:1491-1506. [PMID: 29662288 DOI: 10.3748/wjg.v24.i14.1491] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 15.7] [Reference Citation Analysis]
432 Grossmann M, Wierman ME, Angus P, Handelsman DJ. Reproductive Endocrinology of Nonalcoholic Fatty Liver Disease. Endocr Rev 2019;40:417-46. [PMID: 30500887 DOI: 10.1210/er.2018-00158] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
433 Kartsoli S, Kostara CE, Tsimihodimos V, Bairaktari ET, Christodoulou DK. Lipidomics in non-alcoholic fatty liver disease. World J Hepatol. 2020;12:436-450. [PMID: 32952872 DOI: 10.4254/wjh.v12.i8.436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
434 Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015;1852:1765-78. [DOI: 10.1016/j.bbadis.2015.05.015] [Cited by in Crossref: 127] [Cited by in F6Publishing: 109] [Article Influence: 21.2] [Reference Citation Analysis]
435 Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Loomba R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut. 2016;65:1546-1554. [PMID: 26002934 DOI: 10.1136/gutjnl-2015-309456] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
436 Billeter AT, de la Garza Herrera JR, Scheurlen KM, Nickel F, Billmann F, Müller-Stich BP. MANAGEMENT OF ENDOCRINE DISEASE: Which metabolic procedure? Comparing outcomes in sleeve gastrectomy and Roux-en Y gastric bypass. Eur J Endocrinol 2018;179:R77-93. [PMID: 29764908 DOI: 10.1530/EJE-18-0009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
437 Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathé Z, Gerken G, Paul A, Canbay A, Treckmann JW. Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion. 2012;86:107-113. [PMID: 22846254 DOI: 10.1159/000339344] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
438 Dutkowski P, Linecker M, Deoliveira ML, Müllhaupt B, Clavien P. Challenges to Liver Transplantation and Strategies to Improve Outcomes. Gastroenterology 2015;148:307-23. [DOI: 10.1053/j.gastro.2014.08.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 118] [Article Influence: 22.5] [Reference Citation Analysis]
439 Shengir M, Chen T, Guadagno E, Ramanakumar AV, Ghali P, Deschenes M, Wong P, Krishnamurthy S, Sebastiani G. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis. JGH Open 2021;5:434-45. [PMID: 33860093 DOI: 10.1002/jgh3.12512] [Reference Citation Analysis]
440 Fleming MM, Liu F, Zhang Y, Pei KY. Model for End-Stage Liver Disease Underestimates Morbidity and Mortality in Patients with Ascites Undergoing Colectomy. World J Surg 2018;42:3390-7. [PMID: 29541825 DOI: 10.1007/s00268-018-4591-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
441 Stine JG, Rinella ME. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol 2017;112:752-4. [PMID: 28469217 DOI: 10.1038/ajg.2017.60] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
442 García-Sesma A, Calvo J, Manrique A, Cambra F, Justo I, Caso O, Marcacuzco A, Loinaz C, Jiménez C. Morbidly Obese Patients Awaiting Liver Transplantation-Sleeve Gastrectomy: Safety and Efficacy From a Liver Transplant Unit Experience. Transplant Proc 2019;51:33-7. [PMID: 30598229 DOI: 10.1016/j.transproceed.2018.01.060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
443 van den Berg EH, Douwes RM, de Meijer VE, Schreuder TCMA, Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis. 2018;50:68-75. [PMID: 28935188 DOI: 10.1016/j.dld.2017.08.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
444 Morris MC, Jung AD, Kim Y, Lee TC, Kaiser TE, Thompson JR, Bari K, Shah SA, Cohen RM, Schauer DP, Smith EP, Diwan TS. Delayed Sleeve Gastrectomy Following Liver Transplantation: A 5-Year Experience. Liver Transpl 2019;25:1673-81. [PMID: 31518478 DOI: 10.1002/lt.25637] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
445 Asrani SK, Saracino G, O'leary JG, Gonzales S, Kim PT, Mckenna GJ, Klintmalm G, Trotter J. Recipient characteristics and morbidity and mortality after liver transplantation. Journal of Hepatology 2018;69:43-50. [DOI: 10.1016/j.jhep.2018.02.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
446 Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. J Clin Transl Hepatol. 2015;3:9-16. [PMID: 26356325 DOI: 10.14218/jcth.2015.00001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
447 Henry RK. Growth Hormone Deficiency and Nonalcoholic Fatty Liver Disease with Insights from Humans and Animals: Pediatric Implications. Metabolic Syndrome and Related Disorders 2018;16:507-13. [DOI: 10.1089/met.2018.0056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
448 Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014;20:8377-8392. [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
449 Kwong AJ, Fix OK. Update on the management of the liver transplant patient. Curr Opin Gastroenterol. 2015;31:224-232. [PMID: 25774445 DOI: 10.1097/mog.0000000000000173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
450 Davis BC, Shadab Siddiqui M. Liver Transplantation: the Role of Metabolic Syndrome. Curr Treat Options Gastroenterol. 2017;15:316-331. [PMID: 28432575 DOI: 10.1007/s11938-017-0135-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
451 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? Journal of Hepatology 2018;68:519-25. [DOI: 10.1016/j.jhep.2017.11.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
452 Quillin RC 3rd, Wilson GC, Sutton JM, Hanseman DJ, Paterno F, Cuffy MC, Paquette IM, Diwan TS, Woodle ES, Abbott DE, Shah SA. Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation. Surgery. 2014;156:1049-1056. [PMID: 25239365 DOI: 10.1016/j.surg.2014.06.075] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
453 Zhang S, Sousa A, Lin M, Iwano A, Jain R, Ma B, Lee CM, Park JW, Kamle S, Carlson R, Lee GG, Elias JA, Wands JR. Role of Chitinase 3-Like 1 Protein in the Pathogenesis of Hepatic Insulin Resistance in Nonalcoholic Fatty Liver Disease. Cells 2021;10:201. [PMID: 33498326 DOI: 10.3390/cells10020201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
454 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
455 Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation. 2014;98:216-221. [PMID: 24621538 DOI: 10.1097/tp.0000000000000048] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 6.6] [Reference Citation Analysis]
456 Trunečka P, Míková I, Dlouhá D, Hubáček JA, Honsová E, Kolesár L, Lánská V, Fraňková S, Šperl J, Jirsa M, Poledne R. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Dig Liver Dis 2018;50:490-5. [PMID: 29396131 DOI: 10.1016/j.dld.2017.12.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
457 Im GY, Lubezky N, Facciuto ME, Schiano TD. Surgery in Patients with Portal Hypertension. Clinics in Liver Disease 2014;18:477-505. [DOI: 10.1016/j.cld.2014.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
458 Hempel M, Schmitz A, Winkler S, Kucukoglu O, Brückner S, Niessen C, Christ B. Pathological implications of cadherin zonation in mouse liver. Cell Mol Life Sci 2015;72:2599-612. [DOI: 10.1007/s00018-015-1861-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
459 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
460 Lee Y, Tian C, Lovrics O, Soon MS, Doumouras AG, Anvari M, Hong D. Bariatric surgery before, during, and after liver transplantation: a systematic review and meta-analysis. Surgery for Obesity and Related Diseases 2020;16:1336-47. [DOI: 10.1016/j.soard.2020.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
461 Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Mol Metab. 2017;6:1360-1370. [PMID: 29107284 DOI: 10.1016/j.molmet.2017.09.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
462 Nesher E, Mor E, Shlomai A, Naftaly-Cohen M, Yemini R, Yussim A, Brown M, Keidar A. Simultaneous Liver Transplantation and Sleeve Gastrectomy: Prohibitive Combination or a Necessity? Obes Surg. 2017;27:1387-1390. [PMID: 28281236 DOI: 10.1007/s11695-017-2634-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
463 Hernandez-Alejandro R, Croome KP, Drage M, Sela N, Parfitt J, Chandok N, Marotta P, Dale C, Wall W, Quan D. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol. 2012;18:4145-4149. [PMID: 22919246 DOI: 10.3748/wjg.v18.i31.4145] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
464 Yki-järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The Lancet Diabetes & Endocrinology 2014;2:901-10. [DOI: 10.1016/s2213-8587(14)70032-4] [Cited by in Crossref: 528] [Cited by in F6Publishing: 253] [Article Influence: 75.4] [Reference Citation Analysis]
465 Yang L, Zhou Y, Song H, Zheng P. Jiang-Zhi granules decrease sensitivity to low-dose CCl4 induced liver injury in NAFLD rats through reducing endoplasmic reticulum stress. BMC Complement Altern Med 2019;19:228. [PMID: 31438932 DOI: 10.1186/s12906-019-2641-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
466 Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One 2018;13:e0202226. [PMID: 30161179 DOI: 10.1371/journal.pone.0202226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
467 Li J, Cordero P, Nguyen V, Oben JA. The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease. Integr Med Insights 2016;11:19-25. [PMID: 27147819 DOI: 10.4137/IMI.S31451] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 5.4] [Reference Citation Analysis]
468 Ratziu V. Starting the battle to control non-alcoholic steatohepatitis. Lancet 2015;385:922-4. [PMID: 25468161 DOI: 10.1016/S0140-6736(14)62010-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
469 Silva T, Colombo G, Schiavon L. Adiponectin: A multitasking player in the field of liver diseases. Diabetes & Metabolism 2014;40:95-107. [DOI: 10.1016/j.diabet.2013.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
470 Yokoo T, Browning JD. Fat and Iron Quantification in the Liver: Past, Present, and Future. Topics in Magnetic Resonance Imaging 2014;23:73-94. [DOI: 10.1097/rmr.0000000000000016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
471 Wiesner RH. Evolving trends in liver transplantation: listing and liver donor allocation. Clin Liver Dis 2014;18:519-27. [PMID: 25017073 DOI: 10.1016/j.cld.2014.05.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
472 Theodotou M, Fokianos K, Moniatis D, Kadlenic R, Chrysikou A, Aristotelous A, Mouzouridou A, Diakides J, Stavrou E. Effect of resveratrol on non-alcoholic fatty liver disease. Exp Ther Med 2019;18:559-65. [PMID: 31316594 DOI: 10.3892/etm.2019.7607] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
473 Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant waitlisting in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804-812. [PMID: 28012259 DOI: 10.1002/hep.28923] [Cited by in Crossref: 147] [Cited by in F6Publishing: 117] [Article Influence: 29.4] [Reference Citation Analysis]
474 Romeo S, Sanyal A, Valenti L. Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metabolism 2020;31:35-45. [DOI: 10.1016/j.cmet.2019.12.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 53.0] [Reference Citation Analysis]
475 Cai C, Lin Y, Yu C. Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2019;2019:2096161. [PMID: 31531307 DOI: 10.1155/2019/2096161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
476 Gawrieh S, Chalasani N. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:189-99. [PMID: 29128056 DOI: 10.1016/j.cld.2017.08.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
477 Kang SY, Kim YJ, Park HS. Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998-2035. J Clin Med 2020;9:E2626. [PMID: 32823604 DOI: 10.3390/jcm9082626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
478 Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, McCullough AJ. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015;49:137-44. [PMID: 24583757 DOI: 10.1097/MCG.0000000000000099] [Cited by in Crossref: 99] [Cited by in F6Publishing: 44] [Article Influence: 16.5] [Reference Citation Analysis]
479 van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen H, Jansen PL, Ijzermans JN, Verheij J, van Nieuwkerk CM, Siersema PD, de Man RA. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. European Journal of Gastroenterology & Hepatology 2016;28:352-9. [DOI: 10.1097/meg.0000000000000527] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
480 Li WC, Zhao SX, Ren WG, Zhang YG, Wang RQ, Kong LB, Zhang QS, Nan YM. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice. Exp Ther Med 2021;22:830. [PMID: 34149876 DOI: 10.3892/etm.2021.10262] [Reference Citation Analysis]
481 Thuluvath PJ, Hanish S, Savva Y. Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis. Transplantation 2018;102:656-63. [DOI: 10.1097/tp.0000000000002030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
482 Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res 2018;32:389-400. [PMID: 30355853 DOI: 10.7555/JBR.32.20180045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
483 Cai C, Song X, Yu C. Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease. Cancer Biomark 2020;29:69-78. [PMID: 32623384 DOI: 10.3233/CBM-190169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
484 Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ, Roberts LR, Heimbach JA, Leise MD. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clin Gastroenterol Hepatol. 2017;15:767-775.e3. [PMID: 28013117 DOI: 10.1016/j.cgh.2016.11.034] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 13.8] [Reference Citation Analysis]
485 Sigler MA, Congdon L, Edwards KL. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clin Med Insights Gastroenterol 2018;11:1179552218787502. [PMID: 30013416 DOI: 10.1177/1179552218787502] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
486 Owens MD, Ioannou GN, Tsui JL, Edelman EJ, Greene PA, Williams EC. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. Drug Alcohol Depend 2018;188:79-85. [PMID: 29754030 DOI: 10.1016/j.drugalcdep.2018.03.047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
487 Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71. [PMID: 26469309 DOI: 10.1586/17474124.2016.1099433] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
488 Luo Y, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, Collen R, Idowu M, Contos MJ, Mirshahi F, Daita K, Asgharpour A, Siddiqui MS, Jarai G, Rosen G, Christian R, Sanyal AJ. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Sci Rep. 2018;8:12414. [PMID: 30120271 DOI: 10.1038/s41598-018-30457-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
489 Marjot T, Sbardella E, Moolla A, Hazlehurst JM, Tan GD, Ainsworth M, Cobbold JFL, Tomlinson JW. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabet Med 2018;35:89-98. [DOI: 10.1111/dme.13540] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
490 Cullaro G, Sharma P, Jo J, Rassiwala J, VanWagner LB, Wong R, Lai JC, Magee J, Schluger A, Barman P, Patel YA, Walter K, Biggins SW, Verna EC. Temporal Trends and Evolving Outcomes After Simultaneous Liver-Kidney Transplantation (SLKT): Results from the US SLKT Consortium. Liver Transpl 2021. [PMID: 34265161 DOI: 10.1002/lt.26232] [Reference Citation Analysis]
491 Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, Lanciault C, Caprioli RM, Abumrad N, Flynn CR. Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis. PLoS One. 2013;8:e57165. [PMID: 23451176 DOI: 10.1371/journal.pone.0057165] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
492 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
493 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
494 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
495 Carril E, Valdecantos MP, Lanzón B, Angulo S, Valverde ÁM, Godzien J, Rupérez FJ. Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet. J Pharm Biomed Anal 2020;178:112958. [PMID: 31718984 DOI: 10.1016/j.jpba.2019.112958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
496 Depner CM, Traber MG, Bobe G, Kensicki E, Bohren KM, Milne G, Jump DB. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice. PLoS One. 2013;8:e83756. [PMID: 24358308 DOI: 10.1371/journal.pone.0083756] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
497 Ajmera VH, Terrault NA, VanWagner LB, Sarkar M, Lewis CE, Carr JJ, Gunderson EP. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. J Hepatol 2019;70:126-32. [PMID: 30392752 DOI: 10.1016/j.jhep.2018.09.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
498 Verbeek J, Lannoo M, Pirinen E, Ryu D, Spincemaille P, Vander Elst I, Windmolders P, Thevissen K, Cammue BPA, van Pelt J, Fransis S, Van Eyken P, Ceuterick-de Groote C, Van Veldhoven PP, Bedossa P, Nevens F, Auwerx J, Cassiman D. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. Gut 2015;64:673-83. [DOI: 10.1136/gutjnl-2014-306748] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
499 Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609. [PMID: 23055155 DOI: 10.1002/hep.26093] [Cited by in Crossref: 769] [Cited by in F6Publishing: 678] [Article Influence: 96.1] [Reference Citation Analysis]
500 Choi YJ, Lee DH, Han KD. Association between high fatty liver index and development of colorectal cancer: a nationwide cohort study with 21,592,374 Korean. Korean J Intern Med 2020;35:1354-63. [PMID: 32264657 DOI: 10.3904/kjim.2018.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Singal AK, Hasanin M, Kaif M, Wiesner R, Kuo YF. Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States. Transplantation. 2016;100:607-612. [PMID: 26479282 DOI: 10.1097/tp.0000000000000945] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 11.4] [Reference Citation Analysis]
502 Siddiqui MS, Sterling RK. Posttransplant metabolic syndrome. Int J Hepatol. 2012;2012:891516. [PMID: 23227347 DOI: 10.1155/2012/891516] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
503 Satapathy SK, Nair S, Vanatta JM. Nonalcoholic fatty liver disease following liver transplantation. Hepatol Int 2013;7:400-12. [PMID: 26201774 DOI: 10.1007/s12072-013-9434-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
504 Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr Opin Organ Transplant. 2018;23:169-174. [PMID: 29356708 DOI: 10.1097/mot.0000000000000502] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
505 Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, Ajmera V, Bettencourt R, Collier S, Hooker J, Sy E, Rizo E, Richards L, Sirlin CB, Loomba R. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348-1359. [PMID: 29108123 DOI: 10.1002/hep.29639] [Cited by in Crossref: 108] [Cited by in F6Publishing: 92] [Article Influence: 36.0] [Reference Citation Analysis]
506 Majeed M, Majeed S, Nagabhushanam K, Lawrence L, Mundkur L. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. Sci Rep 2020;10:7440. [PMID: 32366854 DOI: 10.1038/s41598-020-64293-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
507 Whang E, Liu Y, Kageyama S, Woo SL, Yang J, Lee R, Li Z, Ji H, Chen Y, Kupiec-Weglinski JW. Vertical Sleeve Gastrectomy Attenuates the Progression of Non-Alcoholic Steatohepatitis in Mice on a High-Fat High-Cholesterol Diet. Obes Surg 2019;29:2420-9. [PMID: 30982168 DOI: 10.1007/s11695-019-03860-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
508 Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, Bursulaya B, Hernandez ED, Wu J, Prashad M, Schlama T, Liu Y, Chu A, Schmeits J, Huang DJ, Hill R, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Liu B, Richmond W, Sancho-Martinez I, Phimister A, Seidel HM, Badman MK, Joseph SB, Laffitte B, Molteni V. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 2020;63:3868-80. [PMID: 31940200 DOI: 10.1021/acs.jmedchem.9b01621] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
509 Stine JG, Argo CK, Pelletier SJ, Maluf DG, Caldwell SH, Northup PG. Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017;9:139-146. [PMID: 28217250 DOI: 10.4254/wjh.v9.i3.139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
510 Hu W, Ma X, Zhou W, Li X, Sun T, Sun H. Preventive effect of Silibinin in combination with Pu-erh tea extract on non-alcoholic fatty liver disease in ob/ob mice. Food Funct 2017;8:1105-15. [DOI: 10.1039/c6fo01591c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
511 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. [PMID: 26707365 DOI: 10.1002/hep.28431] [Cited by in Crossref: 3251] [Cited by in F6Publishing: 2743] [Article Influence: 650.2] [Reference Citation Analysis]
512 Goossens N, Jornayvaz FR. Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1077. [PMID: 28956824 DOI: 10.3390/nu9101077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
513 Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988-997. [PMID: 22652341 DOI: 10.1016/j.drudis.2012.05.012] [Cited by in Crossref: 175] [Cited by in F6Publishing: 150] [Article Influence: 19.4] [Reference Citation Analysis]
514 Sharpton SR, Feng S, Hameed B, Yao F, Lai JC. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation. 2014;98:557-562. [PMID: 24717221 DOI: 10.1097/tp.0000000000000090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
515 Jacobs A, Warda A, Verbeek J, Cassiman D, Spincemaille P. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. Current Protocols in Mouse Biology 2016;6:185-200. [DOI: 10.1002/cpmo.3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
516 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
517 Chedid MF. Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA. Dig Dis Sci. 2017;62:2621-2622. [PMID: 28840385 DOI: 10.1007/s10620-017-4724-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
518 Boudinaud C, Abergel A, Joubert-Zakeyh J, Fontarensky M, Pereira B, Chauveau B, Garcier JM, Chabrot P, Boyer L, Magnin B. Quantification of steatosis in alcoholic and nonalcoholic fatty liver disease: Evaluation of four MR techniques versus biopsy. Eur J Radiol. 2019;118:169-174. [PMID: 31439237 DOI: 10.1016/j.ejrad.2019.07.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
519 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20:12956-12980. [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 82] [Article Influence: 17.3] [Reference Citation Analysis]
520 Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Abdelmalek M, Doo E, Tonascia JA, Kleiner DE, Sanyal AJ, Chalasani N; NASH Clinical Research Network. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67:134-44. [PMID: 28859228 DOI: 10.1002/hep.29489] [Cited by in Crossref: 100] [Cited by in F6Publishing: 66] [Article Influence: 25.0] [Reference Citation Analysis]
521 Reddy SK, Steel JL, Chen H, Demateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19. [DOI: 10.1002/hep.25536] [Cited by in Crossref: 124] [Cited by in F6Publishing: 108] [Article Influence: 13.8] [Reference Citation Analysis]
522 VanWagner LB, Uttal S, Lapin B, Lee J, Jichlinski A, Subramanian T, Heldman M, Poole B, Bustamante E, Gunasekaran S, Tapia CS, Veerappan A, Wong SY, Levitsky J. Use of Six-Minute Walk Test to Measure Functional Capacity After Liver Transplantation. Phys Ther 2016;96:1456-67. [PMID: 27055540 DOI: 10.2522/ptj.20150376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
523 Plaza-Díaz J, Solis-Urra P, Aragón-Vela J, Rodríguez-Rodríguez F, Olivares-Arancibia J, Álvarez-Mercado AI. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines 2021;9:145. [PMID: 33546191 DOI: 10.3390/biomedicines9020145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
524 Thuluvath PJ, Hanish S, Savva Y. Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis. Transplantation. 2019;103:113-121. [PMID: 29985186 DOI: 10.1097/tp.0000000000002355] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
525 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
526 Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis 2015;19:1-22. [PMID: 25454294 DOI: 10.1016/j.cld.2014.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
527 Dichtel LE, Eajazi A, Miller KK, Torriani M, Bredella MA. Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity. J Comput Assist Tomogr 2016;40:678-82. [PMID: 27116479 DOI: 10.1097/RCT.0000000000000423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
528 Wong VW. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol. 2013;28:18-23. [PMID: 23094755 DOI: 10.1111/jgh.12011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
529 Sourianarayanane A, Arikapudi S, McCullough AJ, Humar A. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. Eur J Gastroenterol Hepatol. 2017;29:481-487. [PMID: 28253211 DOI: 10.1097/meg.0000000000000820] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
530 Tsuchiya T, Naitoh T, Nagao M, Tanaka N, Watanabe K, Imoto H, Miyachi T, Motoi F, Unno M. Increased Bile Acid Signals After Duodenal-Jejunal Bypass Improve Non-alcoholic Steatohepatitis (NASH) in a Rodent Model of Diet-Induced NASH. Obes Surg 2018;28:1643-52. [PMID: 29235014 DOI: 10.1007/s11695-017-3065-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
531 Young K, Aguilar M, Gish R, Younossi Z, Saab S, Bhuket T, Liu B, Ahmed A, Wong RJ. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. Liver Transpl. 2016;22:1356-1366. [PMID: 27348270 DOI: 10.1002/lt.24507] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
532 Carter D, Dieterich DT, Chang C. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. Clin Liver Dis 2018;22:213-27. [PMID: 29128058 DOI: 10.1016/j.cld.2017.08.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
533 Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int 2019;39:924-32. [PMID: 30253043 DOI: 10.1111/liv.13974] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 14.5] [Reference Citation Analysis]
534 Zamora-Valdes D, Watt KD, Kellogg TA, Poterucha JJ, Di Cecco SR, Francisco-Ziller NM, Taner T, Rosen CB, Heimbach JK. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology. 2018;68:485-495. [PMID: 29457842 DOI: 10.1002/hep.29848] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
535 Wong VW, Wong GL, Chan HY, Yeung DK, Chan RS, Chim AM, Chan CK, Tse YK, Woo J, Chu WC. Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. Aliment Pharmacol Ther. 2015;42:731-740. [PMID: 26202818 DOI: 10.1111/apt.13327] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
536 Lombardi AC, Mente ED, Sankarankutty AK, Souza FF, Teixeira AC, Cagnolati D, Souza ME, Silva Ode C Jr. Analysis of 83 consecutive liver transplants performed at a tertiary care reference hospital in the interior of the state of Sao Paulo. Acta Cir Bras 2011;26:530-4. [PMID: 22042119 DOI: 10.1590/s0102-86502011000600020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
537 Xanthakos SA. Noninvasive Assessment of Nonalcoholic Steatohepatitis and Nonalcoholic Steatohepatitis-Related Fibrosis: Is There a Role for Cytokeratin 18? Journal of Pediatric Gastroenterology & Nutrition 2016;63:167-8. [DOI: 10.1097/mpg.0000000000001193] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
538 Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717-30. [DOI: 10.1053/j.gastro.2019.01.042] [Cited by in Crossref: 245] [Cited by in F6Publishing: 180] [Article Influence: 122.5] [Reference Citation Analysis]
539 Samji NS, Verma R, Keri KC, Singal AK, Ahmed A, Rinella M, Bernstein D, Abdelmalek MF, Satapathy SK. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci 2019;64:3413-30. [PMID: 31312990 DOI: 10.1007/s10620-019-05716-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
540 Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM, Michalak S, Bonnafous S, Michielsen P, Oberti F, Iannelli A, Van Gaal L, Patouraux S, Blanchet O, Verrijken A, Gual P, Rousselet M, Driessen A, Hunault G, Bertrais S, Tran A, Calès P, Francque S. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther 2018;47:1387-96. [DOI: 10.1111/apt.14621] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
541 Agbim U, Jiang Y, Kedia SK, Singal AK, Ahmed A, Bhamidimarri KR, Bernstein DE, Harrison SA, Younossi ZM, Satapathy SK. Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis. Liver Transpl. 2019;25:68-78. [PMID: 30091296 DOI: 10.1002/lt.25322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
542 Méndez-Sánchez N, Córdova-Gallardo J, Barranco-Fragoso B, Eslam M. Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis. Front Immunol 2021;12:641240. [PMID: 33833761 DOI: 10.3389/fimmu.2021.641240] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
543 Patel SS, Lin FP, Rodriguez VA, Bhati C, John BV, Pence T, Siddiqui MB, Sima AP, Abbate A, Reichman T, Siddiqui MS. The relationship between coronary artery disease and cardiovascular events early after liver transplantation. Liver Int 2019;39:1363-71. [PMID: 30848862 DOI: 10.1111/liv.14092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
544 Bhadoria AS, Kedarisetty CK, Bihari C, Kumar G, Jindal A, Bhardwaj A, Shasthry V, Vyas T, Benjamin J, Sharma S. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study. Liver Int. 2017;37:1397-1404. [PMID: 28231412 DOI: 10.1111/liv.13396] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
545 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
546 Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726-735. [PMID: 24316260 DOI: 10.1053/j.gastro.2013.11.049.[epub] [Reference Citation Analysis]
547 Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol. 2015;13:2062-2070. [PMID: 26226097 DOI: 10.1016/j.cgh.2015.07.029] [Cited by in Crossref: 159] [Cited by in F6Publishing: 128] [Article Influence: 26.5] [Reference Citation Analysis]
548 Bertasso IM, Pietrobon CB, Lopes BP, Peixoto TC, Soares PN, Oliveira E, Manhães AC, Bonfleur ML, Balbo SL, Cabral SS, Gabriel Kluck GE, Atella GC, Gaspar de Moura E, Lisboa PC. Programming of hepatic lipid metabolism in a rat model of postnatal nicotine exposure – Sex-related differences. Environmental Pollution 2020;258:113781. [DOI: 10.1016/j.envpol.2019.113781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
549 Newton KP, Hou J, Crimmins NA, Lavine JE, Barlow SE, Xanthakos SA, Africa J, Behling C, Donithan M, Clark JM, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network. Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. JAMA Pediatr 2016;170:e161971. [PMID: 27478956 DOI: 10.1001/jamapediatrics.2016.1971] [Cited by in Crossref: 103] [Cited by in F6Publishing: 77] [Article Influence: 20.6] [Reference Citation Analysis]
550 Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405. [PMID: 25557690 DOI: 10.1002/hep.27678] [Cited by in Crossref: 213] [Cited by in F6Publishing: 186] [Article Influence: 35.5] [Reference Citation Analysis]
551 Patterson RE, Kalavalapalli S, Williams CM, Nautiyal M, Mathew JT, Martinez J, Reinhard MK, McDougall DJ, Rocca JR, Yost RA, Cusi K, Garrett TJ, Sunny NE. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. Am J Physiol Endocrinol Metab. 2016;310:E484-E494. [PMID: 26814015 DOI: 10.1152/ajpendo.00492.2015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 13.8] [Reference Citation Analysis]
552 Munteanu MA, Mircea PA. From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome? Clujul Med 2014;87:80-6. [PMID: 26528002 DOI: 10.15386/cjmed-277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
553 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
554 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839.2014.12.06] [Cited by in F6Publishing: 73] [Reference Citation Analysis]
555 Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:9026-9037. [PMID: 25083076 DOI: 10.3748/wjg.v20.i27.9026] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
556 Newsome PN. Entering the GOLDEN Age for Therapies in NASH. Gastroenterology 2016;150:1073-6. [PMID: 27018488 DOI: 10.1053/j.gastro.2016.03.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
557 Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017;23:1015-1022. [PMID: 28340509 DOI: 10.1002/lt.24764] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
558 Berzigotti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis. J Hepatol 2014;60:910-2. [PMID: 24486330 DOI: 10.1016/j.jhep.2014.01.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
559 Jeyapal S, Putcha UK, Mullapudi VS, Ghosh S, Sakamuri A, Kona SR, Vadakattu SS, Madakasira C, Ibrahim A. Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats. Eur J Nutr. 2018;57:2171-2187. [PMID: 28676973 DOI: 10.1007/s00394-017-1492-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
560 Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol 2020;26:7046-60. [PMID: 33311949 DOI: 10.3748/wjg.v26.i44.7046] [Reference Citation Analysis]
561 Idowu MO, Chhatrala R, Siddiqui MB, Driscoll C, Stravitz RT, Sanyal AJ, Bhati C, Sargeant C, Luketic VA, Sterling RK. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients. Liver Transpl. 2015;21:1395-1402. [PMID: 26228654 DOI: 10.1002/lt.24223] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
562 Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510:84-91. [PMID: 24899308 DOI: 10.1038/nature13478] [Cited by in Crossref: 621] [Cited by in F6Publishing: 528] [Article Influence: 88.7] [Reference Citation Analysis]
563 Soleimani D, Paknahad Z, Rouhani MH. Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial. Diabetes Metab Syndr Obes 2020;13:2389-97. [PMID: 32753923 DOI: 10.2147/DMSO.S254555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
564 Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta. 2012;1821:809-818. [PMID: 22056763 DOI: 10.1016/j.bbalip.2011.10.016] [Cited by in Crossref: 161] [Cited by in F6Publishing: 149] [Article Influence: 16.1] [Reference Citation Analysis]
565 Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology 2017;11:357-69. [DOI: 10.1080/17474124.2017.1293523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
566 Gilliland T, Dufour S, Shulman GI, Petersen KF, Emre SH. Resolution of non-alcoholic steatohepatitis after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism. Pediatr Transplant 2016;20:1157-63. [PMID: 27762491 DOI: 10.1111/petr.12819] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
567 Wong GL, Wong VW. Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis. Dig Dis Sci 2015;60:9-12. [DOI: 10.1007/s10620-014-3429-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
568 Engstler AJ, Sellmann C, Jin CJ, Brandt A, Herz K, Priebs J, Bergheim I. Treatment with alpha-galactosylceramide protects mice from early onset of nonalcoholic steatohepatitis: Role of intestinal barrier function. Mol Nutr Food Res 2017;61. [PMID: 28067024 DOI: 10.1002/mnfr.201600985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
569 Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239-1250. [PMID: 25482832 DOI: 10.1002/hep.27647] [Cited by in Crossref: 216] [Cited by in F6Publishing: 195] [Article Influence: 36.0] [Reference Citation Analysis]
570 Ratziu V. Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int 2017;37 Suppl 1:90-6. [PMID: 28052636 DOI: 10.1111/liv.13311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
571 Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Emerging drugs for non-alcoholic steatohepatitis. Expert Opin Emerg Drugs. 2013;18:279-290. [PMID: 23848366 DOI: 10.1517/14728214.2013.811232] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
572 Pearlman M, Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014;30:223-237. [PMID: 24717764 DOI: 10.1097/mog.0000000000000060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
573 Liu A, Galoosian A, Kaswala D, Li AA, Gadiparthi C, Cholankeril G, Kim D, Ahmed A. Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. J Clin Transl Hepatol. 2018;6:420-424. [PMID: 30637220 DOI: 10.14218/jcth.2018.00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
574 Satapathy SK, Tran QT, Kovalic AJ, Bontha SV, Jiang Y, Kedia S, Karri S, Mupparaju V, Podila PSB, Verma R, Maluf D, Mas V, Nair S, Eason JD, Bridges D, Kleiner DE. Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation. Clin Transl Gastroenterol 2021;12:e00302. [PMID: 33555168 DOI: 10.14309/ctg.0000000000000302] [Reference Citation Analysis]
575 Kemmer N, Neff GW, Franco E, Osman-Mohammed H, Leone J, Parkinson E, Cece E, Alsina A. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation. 2013;96:860-862. [PMID: 24247899 DOI: 10.1097/01.tp.0000436723.59879.01] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
576 Luger M, Kruschitz R, Marculescu R, Haslacher H, Hoppichler F, Kallay E, Kienbacher C, Klammer C, Kral M, Langer F, Luger E, Prager G, Trauner M, Traussnigg S, Würger T, Schindler K, Ludvik B. The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial. Trials 2015;16:328. [PMID: 26242295 DOI: 10.1186/s13063-015-0877-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
577 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
578 Sanyal AJ. The fibrosis benefit index for assessment of therapeutic benefit in non-alcoholic steatohepatitis. The Lancet Gastroenterology & Hepatology 2017;2:241-3. [DOI: 10.1016/s2468-1253(17)30005-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
579 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485. [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006] [Cited by in Crossref: 390] [Cited by in F6Publishing: 254] [Article Influence: 65.0] [Reference Citation Analysis]
580 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Reference Citation Analysis]
581 Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA, Osman MM, Mahmoud AO, Almobarak AO. Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System. Gastroenterology Res 2017;10:271-9. [PMID: 29118867 DOI: 10.14740/gr913w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
582 Brouwers MCGJ, Jacobs C, Bast A, Stehouwer CDA, Schaper NC. Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword? Trends Mol Med 2015;21:583-94. [PMID: 26432016 DOI: 10.1016/j.molmed.2015.08.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
583 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
584 Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20:205-214. [PMID: 27063264 DOI: 10.1016/j.cld.2015.10.001] [Cited by in Crossref: 247] [Cited by in F6Publishing: 205] [Article Influence: 41.2] [Reference Citation Analysis]
585 Shaked O, Demetris J, Levitsky J, Feng S, Loza BL, Punch J, Reyes J, Klintmalm G, Jackson W, DesMarais M, Sayre P, Shaked A, Reddy KR. Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation. Transplantation 2021. [PMID: 33982909 DOI: 10.1097/TP.0000000000003681] [Reference Citation Analysis]
586 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
587 Gerhard GS, Davis B, Wu X, Hanson A, Wilhelmsen D, Piras IS, Still CD, Chu X, Petrick AT, DiStefano JK. Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis. Biochem Biophys Rep 2020;22:100753. [PMID: 32258441 DOI: 10.1016/j.bbrep.2020.100753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
588 Kardashian AA, Dodge JL, Roberts J, Brandman D. Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int 2018;38:553-63. [DOI: 10.1111/liv.13523] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
589 Vatner DF, Weismann D, Beddow SA, Kumashiro N, Erion DM, Liao XH, Grover GJ, Webb P, Phillips KJ, Weiss RE, Bogan JS, Baxter J, Shulman GI, Samuel VT. Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab 2013;305:E89-100. [PMID: 23651850 DOI: 10.1152/ajpendo.00573.2012] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
590 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
591 Liu F, Goh GB, Tiniakos D, Wee A, Leow W, Zhao J, Rao H, Wang X, Wang Q, Wan W, Lim K, Romero‐gomez M, Petta S, Bugianesi E, Tan C, Harrison SA, Anstee QM, Chang PJ, Wei L. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. Hepatology 2020;71:1953-66. [DOI: 10.1002/hep.30986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
592 Loggi E, Conti F, Cucchetti A, Ercolani G, Pinna AD, Andreone P. Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature. World J Gastroenterol. 2016;22:8010-8016. [PMID: 27672295 DOI: 10.3748/wjg.v22.i35.8010] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
593 Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int. 2017;37:317-327. [PMID: 27634369 DOI: 10.1111/liv.13255] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
594 Carino A, Cipriani S, Marchianò S, Biagioli M, Scarpelli P, Zampella A, Monti MC, Fiorucci S. Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. Sci Rep 2017;7:13689. [PMID: 29057935 DOI: 10.1038/s41598-017-13102-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
595 Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology 2019;70:511-21. [PMID: 30125379 DOI: 10.1002/hep.30226] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
596 Yang ZR, Wang HF, Zuo TC, Guan LL, Dai N. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats. BMC Pharmacol Toxicol 2016;17:16. [PMID: 27075663 DOI: 10.1186/s40360-016-0059-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
597 Cipolletta S, Entilli L, Nucci M, Feltrin A, Germani G, Cillo U, Volpe B. Psychosocial Support in Liver Transplantation: A Dyadic Study With Patients and Their Family Caregivers. Front Psychol 2019;10:2304. [PMID: 31649602 DOI: 10.3389/fpsyg.2019.02304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
598 Semmler G, Scheiner B, Schwabl P, Bucsics T, Paternostro R, Chromy D, Stättermayer AF, Trauner M, Mandorfer M, Ferlitsch A, Reiberger T. The impact of hepatic steatosis on portal hypertension. PLoS One 2019;14:e0224506. [PMID: 31693695 DOI: 10.1371/journal.pone.0224506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
599 De Fré CH, De Fré MA, Kwanten WJ, Op de Beeck BJ, Van Gaal LF, Francque SM. Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?: Sarcopenia in patients with NAFLD. Obesity Reviews 2019;20:353-63. [DOI: 10.1111/obr.12776] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
600 Buckley AJ, Thomas EL, Lessan N, Trovato FM, Trovato GM, Taylor-robinson SD. Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Research and Clinical Practice 2018;144:144-52. [DOI: 10.1016/j.diabres.2018.08.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
601 Niu B, He K, Li P, Gong J, Zhu X, Ye S, Ou Z, Ren G. SIRT1 upregulation protects against liver injury induced by a HFD through inhibiting CD36 and the NF‑κB pathway in mouse kupffer cells. Mol Med Rep 2018;18:1609-15. [PMID: 29845302 DOI: 10.3892/mmr.2018.9088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
602 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 251] [Article Influence: 150.5] [Reference Citation Analysis]
603 Kogiso T, Tokushige K. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:516. [PMID: 33572797 DOI: 10.3390/cancers13030516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
604 Cabrera D, Ruiz A, Cabello-Verrugio C, Brandan E, Estrada L, Pizarro M, Solis N, Torres J, Barrera F, Arrese M. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1. Dig Dis Sci. 2016;61:3190-3198. [PMID: 27572941 DOI: 10.1007/s10620-016-4285-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
605 D'Ambrosio R, Campi I, Maggioni M, Perbellini R, Giammona E, Stucchi R, Borghi M, Degasperi E, De Silvestri A, Persani L, Fugazzola L, Lampertico P. The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). PLoS One 2021;16:e0249614. [PMID: 33822817 DOI: 10.1371/journal.pone.0249614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
606 González IA, Hartley CP, Nalbantoglu I. Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft. Am J Clin Pathol 2021;155:435-45. [PMID: 33252121 DOI: 10.1093/ajcp/aqaa147] [Reference Citation Analysis]
607 Hellerbrand C, Schattenberg JM, Peterburs P, Lechner A, Brignoli R. The potential of silymarin for the treatment of hepatic disorders. Clin Phytosci 2017;2. [DOI: 10.1186/s40816-016-0019-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 4.2] [Reference Citation Analysis]
608 Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Valasek M, Haufe W, Hooker C, Richards L, Sirlin CB, Loomba R. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2016;9:692-701. [PMID: 27582882 DOI: 10.1177/1756283X16656735] [Cited by in Crossref: 80] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
609 Hu M, Phan F, Bourron O, Ferré P, Foufelle F. Steatosis and NASH in type 2 diabetes. Biochimie 2017;143:37-41. [DOI: 10.1016/j.biochi.2017.10.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
610 Barbara M, Scott A, Alkhouri N. New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2018;7:372-81. [PMID: 30498712 DOI: 10.21037/hbsn.2018.08.05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
611 Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019;84:105803. [PMID: 31260793 DOI: 10.1016/j.cct.2019.06.017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 28.0] [Reference Citation Analysis]
612 Watt KD. Keys to long-term care of the liver transplant recipient. Nat Rev Gastroenterol Hepatol 2015;12:639-48. [DOI: 10.1038/nrgastro.2015.172] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
613 Germani G, Laryea M, Rubbia-Brandt L, Egawa H, Burra P, OʼGrady J, Watt KD. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. Transplantation 2019;103:57-67. [PMID: 30335694 DOI: 10.1097/TP.0000000000002485] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 11.5] [Reference Citation Analysis]
614 Lara J, Teka MA, Sims S, Xia GL, Ramachandran S, Khudyakov Y. HCV adaptation to HIV coinfection. Infect Genet Evol 2018;65:216-25. [PMID: 30075255 DOI: 10.1016/j.meegid.2018.07.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
615 Goh GB, Kwan C, Lim SY, Venkatanarasimha NK, Abu-Bakar R, Krishnamoorthy TL, Shim HH, Tay KH, Chow WC. Perceptions of non-alcoholic fatty liver disease - an Asian community-based study. Gastroenterol Rep (Oxf). 2016;4:131-135. [PMID: 26463276 DOI: 10.1093/gastro/gov047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
616 Romero-gómez M, Zelber-sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of Hepatology 2017;67:829-46. [DOI: 10.1016/j.jhep.2017.05.016] [Cited by in Crossref: 360] [Cited by in F6Publishing: 277] [Article Influence: 90.0] [Reference Citation Analysis]
617 Arya A, Hernandez-Alejandro R, Marotta P, Uhanova J, Chandok N. Recipient ineligibility after liver transplantation assessment: a single centre experience. Can J Surg. 2013;56:E39-E43. [PMID: 23706857 DOI: 10.1503/cjs.004512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
618 Santamarina AB, Oliveira JL, Silva FP, Carnier J, Mennitti LV, Santana AA, de Souza GH, Ribeiro EB, Oller do Nascimento CM, Lira FS. Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet. PLoS One. 2015;10:e0141227. [PMID: 26536464 DOI: 10.1371/journal.pone.0141227] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
619 VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, Vos MB, Speliotes E, Terrault NA, Rinella ME, Lloyd-Jones DM, Allen NB. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int 2018;38:706-14. [PMID: 28963767 DOI: 10.1111/liv.13603] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
620 Liu L, Yu Y, Zhao M, Zheng D, Zhang X, Guan Q, Xu C, Gao L, Zhao J, Zhang H. Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. Int J Endocrinol 2017;2017:5753039. [PMID: 28473851 DOI: 10.1155/2017/5753039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
621 Chen KL, Madak-erdogan Z. Estrogens and female liver health. Steroids 2018;133:38-43. [DOI: 10.1016/j.steroids.2017.10.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
622 Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013;18:251-258. [PMID: 23652610 DOI: 10.1097/mot.0b013e3283615d30] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
623 Snyder HS, Sakaan SA, March KL, Siddique O, Cholankeril R, Cummings CD, Gadiparthi C, Satapathy SK, Ahmed A, Cholankeril G. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J Clin Transl Hepatol. 2018;6:168-174. [PMID: 29951362 DOI: 10.14218/jcth.2017.00050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
624 Ali I, Slizgi JR, Kaullen JD, Ivanovic M, Niemi M, Stewart PW, Barritt AS 4th, Brouwer KLR. Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate. Clin Pharmacol Ther 2017. [PMID: 29271075 DOI: 10.1002/cpt.997] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
625 Patel R, Baker SS, Liu W, Desai S, Alkhouri R, Kozielski R, Mastrandrea L, Sarfraz A, Cai W, Vlassara H. Effect of dietary advanced glycation end products on mouse liver. PLoS One. 2012;7:e35143. [PMID: 22496902 DOI: 10.1371/journal.pone.0035143] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
626 Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881-891; quiz 892. [PMID: 23381014 DOI: 10.1038/ajg.2013.5] [Cited by in Crossref: 181] [Cited by in F6Publishing: 149] [Article Influence: 22.6] [Reference Citation Analysis]
627 VanWagner LB, Terry JG, Chow LS, Alman AC, Kang H, Ingram KH, Shay C, Lewis CE, Bryan RN, Launer LJ, Jeffrey Carr J. Nonalcoholic fatty liver disease and measures of early brain health in middle-aged adults: The CARDIA study. Obesity (Silver Spring). 2017;25:642-651. [PMID: 28169509 DOI: 10.1002/oby.21767] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
628 Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71. [DOI: 10.1016/j.metabol.2016.01.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 7.6] [Reference Citation Analysis]
629 Yang W, Cao M, Mao X, Wei X, Li X, Chen G, Zhang J, Wang Z, Shi J, Huang H, Yao X, Liu C. Alternate-day fasting protects the livers of mice against high-fat diet–induced inflammation associated with the suppression of Toll-like receptor 4/nuclear factor κB signaling. Nutrition Research 2016;36:586-93. [DOI: 10.1016/j.nutres.2016.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
630 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
631 Min HK, Mirshahi F, Verdianelli A, Pacana T, Patel V, Park CG, Choi A, Lee JH, Park CB, Ren S, Sanyal AJ. Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2015;308:G794-803. [PMID: 25747354 DOI: 10.1152/ajpgi.00390.2014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
632 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020;161:bqaa134. [PMID: 32776116 DOI: 10.1210/endocr/bqaa134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
633 Henry RK. When They're Done Growing, Don't Forget They May Still Need Growth Hormone. Metab Syndr Relat Disord 2021;19:257-63. [PMID: 33596132 DOI: 10.1089/met.2020.0130] [Reference Citation Analysis]
634 Santamarina AB, Carvalho-Silva M, Gomes LM, Okuda MH, Santana AA, Streck EL, Seelaender M, do Nascimento CM, Ribeiro EB, Lira FS, Oyama LM. Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice. J Nutr Biochem 2015;26:1348-56. [PMID: 26300331 DOI: 10.1016/j.jnutbio.2015.07.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
635 Gallegos-orozco JF, Charlton MR. Predictors of Cardiovascular Events After Liver Transplantation. Clinics in Liver Disease 2017;21:367-79. [DOI: 10.1016/j.cld.2016.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
636 Yoo ER, Perumpail RB, Cholankeril G, Jayasekera CR, Ahmed A. The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C. Telemed J E Health 2017;23:870-3. [PMID: 28375820 DOI: 10.1089/tmj.2016.0189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
637 Halegoua-De Marzio DL, Herrine SK. Training the next generation of hepatologist: What will they need to know? Clin Liver Dis (Hoboken) 2015;5:129-31. [PMID: 31040968 DOI: 10.1002/cld.461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
638 Gawrieh S, Chalasani N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:338-48. [PMID: 26378648 DOI: 10.1055/s-0035-1562951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
639 Caussy C, Johansson L. Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Endocrinol Diabetes Metab. 2020;3:e00134. [PMID: 33102797 DOI: 10.1002/edm2.134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
640 Li LC, Hsu CN, Lin CC, Cheng YF, Hu TH, Chen DW, Lee CH, Nakano T, Chen CL. Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients. BMC Gastroenterol 2017;17:58. [PMID: 28427351 DOI: 10.1186/s12876-017-0611-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
641 van Koppen A, Verschuren L, van den Hoek AM, Verheij J, Morrison MC, Li K, Nagabukuro H, Costessi A, Caspers MPM, van den Broek TJ, Sagartz J, Kluft C, Beysen C, Emson C, van Gool AJ, Goldschmeding R, Stoop R, Bobeldijk-Pastorova I, Turner SM, Hanauer G, Hanemaaijer R. Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. Cell Mol Gastroenterol Hepatol 2018;5:83-98.e10. [PMID: 29276754 DOI: 10.1016/j.jcmgh.2017.10.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
642 Asrani SK. Liver Transplantation for Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2014;12:403-4. [DOI: 10.1016/j.cgh.2013.11.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
643 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
644 Bauters D, Spincemaille P, Geys L, Cassiman D, Vermeersch P, Bedossa P, Scroyen I, Lijnen HR. ADAMTS5 deficiency protects against non-alcoholic steatohepatitis in obesity. Liver Int 2016;36:1848-59. [PMID: 27254774 DOI: 10.1111/liv.13181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
645 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 845] [Article Influence: 202.2] [Reference Citation Analysis]
646 Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188-2195. [PMID: 24375711 DOI: 10.1002/hep.26986] [Cited by in Crossref: 437] [Cited by in F6Publishing: 369] [Article Influence: 62.4] [Reference Citation Analysis]
647 Suraweera D, Dutson E, Saab S. Liver Transplantation and Bariatric Surgery: Best Approach. Clin Liver Dis. 2017;21:215-230. [PMID: 28364810 DOI: 10.1016/j.cld.2016.12.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
648 Kaswala DH, Zhang J, Liu A, Sundaram V, Liu B, Bhuket T, Wong RJ. A Comprehensive Analysis of Liver Transplantation Outcomes Among Ethnic Minorities in the United States. Journal of Clinical Gastroenterology 2020;54:263-70. [DOI: 10.1097/mcg.0000000000001236] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
649 McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 2017;65:1543-56. [PMID: 28027586 DOI: 10.1002/hep.29025] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 18.0] [Reference Citation Analysis]
650 Pham T, Dick TB, Charlton MR. Nonalcoholic Fatty Liver Disease and Liver Transplantation. Clin Liver Dis 2016;20:403-17. [PMID: 27063277 DOI: 10.1016/j.cld.2015.10.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
651 Fleming MM, DeWane MP, Luo J, Zhang Y, Pei KY. Ascites: A marker for increased surgical risk unaccounted for by the model for end-stage liver disease (MELD) score for general surgical procedures. Surgery 2018;164:233-7. [PMID: 29705097 DOI: 10.1016/j.surg.2018.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
652 Wong RJ, Cheung R, Perumpail RB, Holt EW, Ahmed A. Diabetes mellitus, and not obesity, is associated with lower survival following liver transplantation. Dig Dis Sci. 2015;60:1036-1044. [PMID: 25596720 DOI: 10.1007/s10620-014-3469-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
653 Gao LL, Ma JM, Fan YN, Zhang YN, Ge R, Tao XJ, Zhang MW, Gao QH, Yang JJ. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. Int J Biol Macromol 2021;183:1379-92. [PMID: 33992651 DOI: 10.1016/j.ijbiomac.2021.05.066] [Reference Citation Analysis]
654 Allen AM, Kim WR, Heimbach JK, Rule AD. Reply to: “Chronic kidney disease (CKD) and NAFLD: time for awareness and screening”. J Hepatol. 2015;62:984-985. [PMID: 25529624 DOI: 10.1016/j.jhep.2014.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
655 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
656 Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 2012;9:219-30. [PMID: 22349170 DOI: 10.1038/nrgastro.2012.14] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
657 Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-lotichius M, Zimmermann T, Galle PR, Hansen T, Otto G, Schuchmann M. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation: Metabolic syndrome and NAFLD after liver transplantation. Transplant International 2013;26:67-74. [DOI: 10.1111/j.1432-2277.2012.01576.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]